Systemic Manifestations and Health-Related Quality of Life in Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome-Hypermobility Type by Krahe, Anne
Systemic Manifestations and Health-
Related Quality of Life in Joint 
Hypermobility Syndrome/Ehlers-
Danlos Syndrome-Hypermobility Type 
Anne Krahe 
B.App.Sc (Physiotherapy),  
M.Hlth.Sc (Physiotherapy-Sports) 
 
 
A thesis submitted in fulfillment of the requirements for the 
degree of Master of Philosophy at the University of Sydney. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discipline of Biomedical Science 
Sydney Medical School 
University of Sydney 
 
 
 i 
Candidate’s Certificate 
 
I, Anne Krahe, hereby declare that the work contained within this thesis 
is my own and has not been submitted to any other university or 
institution as part of a whole requirement for any higher degree.  
 
I, Anne Krahe, hereby declare that I was the principal researcher of all 
work included in this thesis, including work under review for publication.  
A statement from co-authors confirming authorship contribution of the 
MPhil candidate provided in the relevant chapter.  
 
I, Anne Krahe, understand that if I am awarded a higher degree for my 
thesis entitled “Systemic Manifestations and Health Related Quality of 
Life in Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome-
Hypermobility Type”, being lodged herewith for examination, the thesis 
will be lodged in the University of Sydney Library and available for 
immediate use.  I agree that the University Librarian (or in the case of the 
department, Head of the Department) may supply a photocopy or 
electronic version of the thesis to an individual for research or study or to 
a library.  
 
Signed: 
 
Date:  3/8/2017 
 
 
 ii 
Supervisor’s Certificate 
 
As supervisor for the candidature upon which this thesis is based, I can 
confirm that the authorship attribution statements above are correct. 
 
This is to certify the thesis entitled “Systemic Manifestations and Health-
Related Quality of Life in Joint Hypermobility Syndrome/Ehlers-Danlos 
Syndrome-Hypermobility Type”, submitted by Anne Krahe in fulfillment 
of the requirements for the degree of Master of Philosophy (Medicine), is 
in a form ready for examination.  
 
 
 
 
 
Associate Professor Leslie Nicholson  
Discipline of Biomedical Sciences  
Sydney Medical School  
University of Sydney  
Date:  3/8/2017 
 
 
 
 
 
 
 iii 
Acknowledgments   I wish to thank my supervisors, Associate Professor Leslie Nicholson and Dr Roger Adams for their support, encouragement, enthusiasm and patience over the course of my studies.  With the initial encouragement from Associate Professor Leslie Nicholson, I undertook this course of study and her ongoing interest, diligence, encouragement and guidance has been instrumental in keeping me focused and completing this thesis.   Dr Roger Adams has eagerly assisted me throughout the last two years of this course of study and I am very grateful for the wealth of knowledge he provides and his ongoing encouragement and enthusiasm towards this field of research.   I would also like to thank and acknowledge the support provided by Dr Bronwyn Ackermann who assisted in the development of the testing protocol for the physical examination component of the study.  Special thanks also goes to Felicia Lim who is a valuable resource of the Discipline of Biomedical Sciences and is always eager to assist and support students in any way she can, she provided me with much needed help and resources on many occasions during my candidature.    I wish to acknowledge all the volunteers who participated in this research, without their eagerness and commitment to furthering the knowledge base in the field of JHS/EDS-HT this thesis would not have been possible.   Lastly I would like to thank my family and friends for the support, encouragement and recognition of my choice to undertaken this course of study and the time commitment it required.  The ongoing reassurance and support of my Mum, Dad, Brother and Sister has provided me with the reassurance, support and confidence I required to complete this thesis.       
 iv 
List of Abbreviations: 
AQoL-6D  Assessment of Quality of Life – 6 Dimension  
BJHS   Benign Joint Hypermobility Syndrome 
CFS   Chronic Fatigue Syndrome 
CI   Confidence Interval  
DASS-21  Depression, Anxiety and Stress Scale – 21 items 
EDS   Ehlers-Danlos Syndrome  
EDS-HT  Ehlers-Danlos Syndrome Hypermobility Type  
FSS   Fatigue Severity Score 
HMS   Hypermobility Syndrome 
GJH   Generalised Joint Hypermobility  
HDCT  Hereditary Disease of the Connective Tissue   
HRQoL  Health-Related Quality of Life  
JHS   Joint Hypermobility Syndrome 
JHS/EDS-HT Joint Hypermobility Syndrome/ Ehlers-Danlos 
Syndrome Hypermobility Type 
MS   Multiple Sclerosis 
PAI   Physical Activity Index 
POP   Pelvic Organ Prolapse 
POTS   Postural Orthostatic Tachycardia Syndrome 
RA   Rheumatoid Arthritis 
SD   Standard Deviation 
SLE   Systemic Lupus Erythematous 
UI   Urinary Incontinence 
VAS   Visual Analogue Scale 
 
 
 
 v 
Abstract 
 
Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome-Hypermobility Type 
(JHS/EDS-HT) is a hereditary connective tissue disorder associated with both 
musculoskeletal and systemic manifestations.  There is increasing recognition of the 
significance of the non-musculoskeletal manifestations of the disorder, such as 
fatigue, orthostatic intolerance, gastrointestinal symptoms and psychological features, 
the presence of which have challenged the historical view of the condition as a 
“benign” disorder characterised only by musculoskeletal and cutaneous features. The 
experience of adults affected by JHS/EDS-HT is often defined by delays in the 
diagnosis of the condition, dissatisfaction with the diagnostic process and symptom 
management and the occurrence of a complex array of systemic manifestations 
associated with the disorder. All of these contribute to a disease morbidity similar to 
that found in other chronic diseases, significant reduction in overall health-related 
quality of life (HRQoL) and the progression to functional impairment and disability in 
some of the adult population affected by the disorder.  Over the past three decades, 
understanding of the disorder has progressed significantly to a point where there is 
now recognition of the multisystem nature of the condition. There is, however, an 
ongoing need to further investigate the prevalence, mechanisms and determinants of 
the systemic manifestations of the condition and the HRQoL experienced by those 
affected by JHS/EDS-HT.  
 
The primary aim of this thesis is to describe the disease profile of JHS/EDS-HT in an 
adult population, to provide future direction for the development of targeted 
management strategies for adults affected by JHS/EDS-HT.  Attention will be focused 
on investigating the prevalence and significance of non-musculoskeletal features of 
the disorder and their relationship with the overall HRQoL reported by those affected. 
The prevalence and factors contributing to the severity of fatigue, psychological 
manifestations of the condition and overall HRQoL, will be a particular focus of this 
project. Multiple regression analysis will be used to help further define manifestations 
of the disorder that are predictive of fatigue severity and HRQoL, in order to inform 
potential future management strategies for the condition.  
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The aims and objectives of this thesis, a review of the current literature relating to 
JHS/EDS-HT, and the historical background to the development diagnostic criteria 
over the past century, are presented in Chapters 1 and 2 of the thesis.   To achieve the 
thesis objectives, two studies were undertaken to investigate the manifestations 
related to JHS/EDS-HT in an adult population, and specifically to investigate the non-
musculoskeletal features of fatigue severity, psychological manifestations of the 
condition, and overall quality of life experienced by those diagnosed with the 
JHS/EDS-HT. 
 
The investigation of the prevalence, severity and identification of possible predictors 
of fatigue severity was undertaken as Study 1 and is found in Chapter 3 of this thesis.  
This study established that significant fatigue was present in 79.5% of participants 
and was identified as the most prevalent systemic manifestation of the disorder, with 
the strongest correlation with overall HRQoL of all reported manifestations. This 
study successfully identified five manifestations contributing to fatigue severity, 
including four that are potentially modifiable, accounting for 52.3% of the variance in 
the severity of the fatigue.  The modifiable predictors of fatigue severity identified 
were; current levels of physical activity participation, satisfaction with the diagnostic 
and management process experienced by individuals, the frequency of reported 
orthostatic dizziness, and levels of participation in community and personal 
relationships, in addition to the self- perceived extent of joint hypermobility identified 
as a non-modifiable feature.  The results of this study provide an important evidence 
base for future research investigating the potential impact of various management 
strategies targeting these identified factors contributing to the experience of fatigue in 
this population.  
 
The systemic nature of JHS/EDS-HT and the multitude of manifestations that are 
associated with the condition have previously been found to be associated with 
reduced HRQoL in this population.  Study 2, which constitutes Chapter 4 of this 
thesis, aimed to identify the features of JHS/EDS-HT associated with overall HRQoL 
and to determine if there are modifiable predictors of HRQoL in this population.  This 
study identified three determinants of HRQoL, including; the number of joints 
affected by pain, the current level of physical activity participation and levels of 
depressive symptoms reported by participants, together accounting for 54.9% of the 
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variance seen in the reported HRQoL of participants.  The results of this study 
provide future direction for interventional studies undertaken with the aim of 
improving the overall HRQoL experienced by this population by targeting these 
modifiable determinants.  
 
A summary of the thesis and concluding remarks are presented in Chapter 5. This 
chapter includes suggestions for future research and clinical interventions in the field 
of JHS/EDS-HT that have arisen as a result of the 2 included studies.   
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Background: 
Generalised Joint Hypermobility (GJH) is characterised by excessive range of motion 
of affected synovial joints when referenced against values considered normal for an 
individual’s age, sex and ethnicity (1).  Affected individuals often refer to themselves 
as “double jointed”. The hypermobility may be performance enhancing in some sports 
and performing arts (e.g. gymnastics, high diving, and dance) where it is sometimes 
seen as a positive selection factor (2). GJH can present as either the extreme of 
normal joint mobility in the absence of any disorder of the connective tissue or as a 
feature of a range of disorders where the underlying cause of joint hypermobility is a 
disorder of the connective tissue. 
 
Joint Hypermobility Syndrome (JHS) and Ehlers-Danlos Syndrome – Hypermobile 
Type (EDS-HT) are chronic connective tissue disorders in which collagen synthesis is 
affected. Since connective tissues are found in many of the body’s organs, these 
syndromes are not only characterized by generalised joint hypermobility but a 
combination of musculoskeletal (e.g. joints, muscles) and multisystem (e.g. skin, 
gastrointestinal, uro-genital) symptoms and signs. There is a growing consensus that 
JHS and EDS-HT are indistinguishable conditions and consequently are the same 
phenotypic disorder (3, 4), referred to as JHS/EDS-HT.  
 
With the progression of research and knowledge relating to JHS/EDS-HT the 
understanding of the condition has evolved from that of a benign process isolated to 
the musculoskeletal system to a systemic condition with the potential to significantly 
reduce the overall quality of life (5) and contribute to substantial disease morbidity (6, 
7). As advancements in research have occurred, the significance of the systemic 
features of JHS/EDS-HT, such as severe fatigue (8), have been noted to be among the 
most incapacitating of all manifestations associated with the disorder (9).  With 
greater appreciation of the systemic manifestations of JHS/EDS-HT it has been 
recognized that future specific research is required to further delineate the 
mechanism, role and impact non-musculoskeletal symptoms have in JHS/EDS-HT. 
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Generalised Joint Hypermobility: 
Identification of Generalised Joint Hypermobility: 
The accurate identification of GJH forms the basis of the diagnosis of JHS/EDS-HT, 
therefore consideration of what constitutes GJH is imperative to thoroughly 
appreciate the disorder.   Despite the identification of GJH as being a significant 
element of the diagnostic process for JHS/EDS-HT and a range of other connective 
tissue disorders, there continues to be a lack of international consensus in establishing 
a definition that adequately describes the presence of excessive synovial joint 
mobility while accounting for sex, age and racial differences observed in normal 
mobility(10). The process of identifying GJH is further complicated by the historical 
use of a range of tools attempting to identify and quantify the presence of GJH (Table 
1.1).   
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Table 1.1 Commonly used clinical tools to detect GJH 
Tool Assessment Protocol  Method of quantifying GJH Cut-off score for GJH and variations 
Carter Wilkinson Test (1, 
11) 
1.Passive apposition of the thumb to flexor aspect of forearm  
2.Passive hyperextension of fingers so parallel to forearm 
3.Passive hyperextension of the elbow >10degrees 
4.Passive hyperextension of the knee >10degrees 
5.Excessive passive Dorsiflexion of the ankle and eversion of the 
foot 
1 point assigned to each positive 
result = /5 
• > 3/5 positive tests in both upper limb and lower 
limb(11) 
• >3/5 positive results in pairs(1) 
Beighton and Horan Test 
(12) 
1.Passive apposition of the thumb to flexor aspect of forearm  
2. Passive hyperextension of the elbow >10degrees 
3 Passive hyperextension of the knee >10degrees 
4. Passive Dorsiflexion of the little finger past 90degrees 
5. Forward flexion of the trunk, with knees extended, so the palms 
rest easily on the floor 
1 point assigned to each positive 
result present bilaterally 
Range 0-5 
No cut-off for GJH described in initial literature(12) 
Rotes Querol et al (13) 1. Passive apposition of the thumb to flexor aspect of forearm >185 
degrees 
2. 2. Passive hyperextension of the elbow >10degrees 
3 Passive hyperextension of the knee >5degrees 
4. Passive dorsiflexion of the 2nd finger so the angle of between the 
table and distal phalanx is >100degrees  
5. Forward flexion of the trunk, with knees extended, so the palms 
rest easily on the floor 
6. Shoulder external rotation > 90 degrees  
7. Cervical spine rotation >90degrees and side flexion greater than 
50degrees  
8. Bilateral hip abduction >90degrees  
9. Dorsiflexion of the metatarsal-phalangeal joint >90degrees 
10. Lateral flexion of the lumbar spine with head and column below 
horizontal plane  
Score range 0-10  Grade severity of GJH: 
• Grade 1: 0-2 
• Grade 2: 3-5 
• Grade 3: 6-7  
• Grade 4: 8-10  
Beighton Score (14) 1.Passive apposition of the thumb to flexor aspect of forearm  
2. Passive hyperextension of the elbow >10degrees 
3 Passive hyperextension of the knee >10degrees 
4. Passive Dorsiflexion of the little finger past 90degrees 
5. Forward flexion of the trunk, with knees extended, so the palms 
rest easily on the floor 
1 point assigned to each positive 
result 
Score range 0-9 
 
• Initial description – no cut-off score identified(14) 
• ≥ 5/9(15) 
• ≥ 4/9(16) 
Hakim-5(17) 
 
1. Can you now (or could you ever) place your hands flat on the 
floor without bending your knees? 
2. Can you now (or could you ever) bend your thumb to touch your 
forearm? 
3. As a child did you amuse your friends by contorting your body 
into strange shapes or could you do the splits? 
4. As a child or teenager did your shoulder or knee cap dislocate on 
more than one occasion? 
5. Do you consider yourself double-jointed? 
Score range from 0 – 5 with one 
point allocated for each positive 
answer.  
 
The Hakim 5 is a Self-assessment 
tool. 
• Cut-off of 2/5 positive responses accurately 
identifies GJH in 84% of cases. 
 5 
The Beighton screening tool is the one most commonly utilised tool in both clinical 
practice and research to identify the presence of GJH (Table 1.2). The protocol for 
assessing the Beighton score allocates a point for each of 4 specific joints bilaterally 
and for forward flexion of the trunk, where any exceed a defined range of motion, 
with a minimum score of 0 and maximum score of 9 possible. The protocol is 
somewhat ambiguous and studies employing it rarely describe in detailed steps 
measures taken to standardise each of the five measures (table of the Beighton 
procedure).  The Beighton Score does however have validity assessing GJH in school-
aged children when range of motion is objectively measured using goniometry (18, 
19),  and has a good to excellent inter-rater (19, 20) and intra-rater reliability (20). 
Table 1.2 Initial description of the Beighton Scoring system (14)  
 Initial description of  Beighton Score  
 
Passive dorsiflexion of the little finger beyond 90degrees 
 
Potential problems with interpretation: 
It is not clear whether the 90 degrees is a composite 
measure at the MCP, PIP and DIP or just at the MCP 
 
Passive apposition of the thumb to the flexor aspect of the 
forearm 
 
Potential problems with interpretation: 
Is apposition of the tip of the thumb sufficient of should the 
entire thumb oppose the forearm? 
 
Hyperextension of the elbows beyond 10 degrees  
 
 
Potential problems with interpretation: 
Is visual estimation accurate at angles close to 10 
degrees? 
 
Hyperextension of the knees beyond 10 degrees 
 
 
Potential problems with interpretation: 
Is visual estimation accurate at angles close to 10 
degrees? 
 
Forward flexion of the trunk, with knees straight, so that 
the palms of the hands rested easily on the floor.  
 
Potential problems with interpretation: 
How far can the hands be placed in front of the feet? 
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Prevalence of Generalised Joint Hypermobility  
Epidemiological studies investigating the prevalence of GJH in the general population 
have identified a number of factors, such as age, sex and race, that can influence the 
extent of joint hypermobility present in otherwise healthy joints. The prevalence of 
GJH in the paediatric population has been documented to range from 19.2% – 64.6% 
(21, 22), while the prevalence in the adult population is estimated to range from 4% - 
29.8% (23, 24). With increasing age it is accepted that joint mobility reduces, while 
females typically present with greater joint mobility than males of the same age and 
gender and race (Table 1.3).  
 
Inconsistencies in the reported prevalence of GJH even in similar samples may be 
explained by the use of different screening tools, non-universal cut-off scores and 
differing application of components of the screening tools to assess GJH.  Research 
utilising the Beighton Score does not have consistency in either the application of the 
components of the test, with the Beighton lacking standardised procedures to define 
how components of the test should be performed (18) or in the use of a uniform cut-
off score to identify the presence of abnormal joint laxity, with scores used in 
literature ranging from ≥3/9 to ≥5/9 (25) (Table 1.3).  Four or more out of nine has 
been generally been identified as the cut-off point to identify individuals who possess 
features consistent with GJH (19). 
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Table 1.3 Prevalence GJH and clinical tools used to establish GJH: 
Study Number of study 
Participants and 
Country undertaken 
Age in years Proportion of 
males with GJH 
Proportion of 
females with GJH 
Total proportion of 
individuals with 
GJH 
Hypermobility Tool utilised 
and Cut-off score 
Lamari et al 2005(21) 1120 
Brazil 
Range 4-7 60% 68.8% 64.6% Beighton  
≥ 4/9 
Clinch et al 2011(22) 6022 
United Kingdom 
Mean 13.8 10.6% 27.5% 19.2% Beighton  
≥ 4/9 
Jansson et al 2004(26) 1845 
Sweden 
9 37.6% 47.9% - Beighton  
≥ 4/9 12 21% 37.8% - 
15 15.5% 53% - 
Al-Rawi et al 
1985(23) 
1774  
Iraq 
Range 20-24 25.4% 35.8% 29.8% Beighton  
≥ 4/9 
Ishaq et al (2010)(27) 1000 
Pakistan 
Mean 25.6 
Range 14-60 
6.7% 7.8% 7% Beighton  
≥ 4/9 
Didia et at 2002(28) 550 
Nigeria 
 Range 17-30 8% 17% 12.91% Beighton  
≥ 5/9 
Seow et al 1999(29) 306 
Singapore 
(Malay/Indian/Chine
se)  
Range 15-39 - - 17% Beighton 
 ≥ 5/9 
Larsson et al 1987(30) 660 
North America 
 
Range 14-68 
- - 9.7% Carter and Wilkinson Test  
≥ 3/5 
Beighton et al 
1973(14) 
502 
South Africa 
 
>20yrs of age 6% 20% 15.7% Nil GJH cut-off specified % 
indicates ≥3/9 Beighton 
Klemp et al 2002(24) 792 
New Zealand 
(Caucasian and 
Maori) 
>5yrs of age 
Female: 
Mean 46.10 
(Caucasian) 
Mean 35.06 (Maori) 
Male: 
Mean 45.54 
(Caucasian) 
Mean 30.49 (Maori) 
2% (Caucasian) 
 
2% (Maori) 
6% (Caucasian) 
 
9% (Maori) 
4% (Caucasian) 
 
6.2% (Maori) 
Beighton  
≥ 4/9 
Kirk et al 1967 (1) 64 
British  
Range 5 - 57 - - 25% Carter and Wilkinson Test  
≥ 3/5 
 8 
The evolution of JHS and EDS-HT as a single clinical entity: 
Recognition of the historical evolution of knowledge relating to GJH associated with 
cutaneous, musculoskeletal and systemic manifestations is crucial in understanding 
the modern day diagnoses of JHS/EDS-HT.  
Early documentation of GJH associated with skin signs: 
The clinical presentation of joint hypermobility has been referenced in literature since 
as early as the 4th Century BC.  At this time, Hippocrates recorded his observations of 
members of the Egyptian Scythian tribe, noting that individuals affected by lax joints 
displayed functional difficulties when throwing javelins and using bows. He noted 
tribe members performed cautery at multiple sites including the shoulder, wrists and 
hips in attempts to stabilise joints affected by laxity.  Apart from the joint laxity, 
Hippocrates made further comment that he observed that male members of this 
population were also affected by joint swelling which resulted in limitations in their 
functional roles in the tribe with respect to tasks normally undertaken by women (31).   
 
In the medical literature there was little reference to joint hypermobility until the turn 
of the 20th Century when, in 1892, Dr Tschernogobow a Russian dermatologist 
provided a comprehensive account of the clinical presentation of two individuals. He 
reported the presence of hypermobility of the large joints with lax and fragile skin, 
that had difficulty holding sutures, and molluscoid pseudo tumours of the knees and 
elbows (32).   A short time later in 1901, Edvard Lauriz Ehlers a Danish 
dermatologist published a case review supporting this presentation, additionally 
noting an increased predisposition to bruising, developmental delay in walking and 
recurrent patella subluxations.  In 1908, Dr Henri-Alexandre Danlos a French 
dermatologist suggested that the previously identified lesions affecting the elbows and 
knees were potentially vascular and inflammatory responses to trauma (32). 
 
In the late 19th century, some individuals presenting with manifestations consistent 
with the modern definitions of EDS, performed in travelling shows, providing 
entertainment by demonstrating their excessive skin and joint laxity (Figure 1.1). As a 
consequence, there was a perception that people exhibiting these signs were “freaks”, 
with the entertainment value creating a perception of a benign condition.  This 
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opinion may have affected the initial recognition of other serious, debilitating signs 
and symptoms, associated with skin and joint laxity, which have later been described 
as a connective tissue dysplasia with diverse phenotypical presentation. 
 
Figure 1.1 Severe skin manifestation in EDS – sufferers portrayed as “freaks” in early 
travelling shows (Left image (33) and Right image(34)).  
Initial identification of a hereditary pattern of expression of GJH: 
The documentation in the rheumatology literature of a potential hereditary pattern in 
the expression of GJH was first made in 1916 when Finkelstein described the clinical 
presentation of an infant with GJH with a positive familial history of joint laxity(35). 
He termed this condition Joint Hypotonia and noted that the condition differed from 
previously documented myotonia, finding no evidence of muscle weakness or reflex 
changes that were associated with the excessive joint hypermobility (35).  The likely 
familial pattern of inheritance of GJH was again documented in 1927 when Albert 
Key suggested a potential sex linked trait after investigating a family where the father 
and all four sons demonstrated joint laxity while female members of the family were 
apparently unaffected by the condition (36). The author described the condition as 
limited to hypermobility, in otherwise health joints, without signs of hereditary 
conditions of the connective tissue.  It is worth noting there was reference to the 
presence of arthralgia in the father and photographic records which demonstrated 
evidence of papyraceous scarring affecting the skin overlying the anterior knee joints 
(36), both of which suggest that the joint hypermobility was potentially associated 
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with both symptomatic joint and cutaneous manifestations.  Multiple authors later 
described the presence of GJH with associated symptomatic joint manifestations.  
Specific links were drawn between GJH and congenital hip dysplasia (11) in addition 
to recurrent patella (37, 38) and shoulder dislocations (37).   
Divergence in the clinical diagnosis related to symptomatic GJH: 
At the turn of the 20th Century, the accounts of research into the clinical presentation 
of symptomatic hypermobility diverged to form two schools of thought that resulted 
in the development of two “distinct” conditions.  The title given to the clinical 
presentation by the field of dermatology in 1936 was EDS (39), while over 30 years 
later in 1967, rheumatologists  labelled the condition Hypermobility Syndrome (1).  
Hypermobility Syndrome has variably been referred to in literature as JHS, BJHS or 
HMS. The clinical sub-domains of the medical field responsible for developing the 
initial diagnoses help to explain the differing initial descriptions of the condition.  The 
dermatologic focus on the significance of cutaneous manifestations of EDS rather 
than joint hypermobility became the basis of the distinction between JHS and EDS in 
early literature.   
Evolution of EDS: 
Weber-Parkes first used the diagnostic label of Ehlers-Danlos Syndrome 1936, 
referring to the condition as a form of congenital developmental mesenchyme 
dysplasia, otherwise referred to as a Hereditary Disease of the Connective Tissue 
(HDCT) (39).  He described three distinct manifestations of the condition – over-
elasticity of the skin, looseness or over-extensibility of joints and friability of the skin 
and blood vessels (39), with a possible fourth feature relating to altered scar formation 
which he hypothesised may be a result of the friable nature of the skin.   
Hypermobility was not seen as pivotal to the diagnosis, instead skin and blood vessel 
manifestations were clearly noted as the predominant symptoms relating to the 
condition (39). Jansen later proposed that the phenotype was best explained by a 
defect of the collagen that comprises connective tissues (40).   
 
The clinical variability observed in EDS prompted the opinion that the diagnosis was 
likely a HCTD with potentially different genotypes (41).  Barabas identified three 
distinct clinical groups that fell under the umbrella of EDS in 1967.  The first was 
titled the Classical type, presenting with severe joint and skin manifestations but no 
 11 
varicose veins or arterial ruptures.   Varicose type referred to the second subgroup of 
EDS where individuals were severely affected by varicosities and only demonstrated 
mild skin and joint involvement.  The arterial subtype of EDS affected the third group 
of individuals, presenting with thin skin, mild skin hyper-extensibility, limited joint 
hypermobility and an ease of bruising.  This subgroup was associated with severe 
arterial ruptures (41).     
 
In 1986, at the 7th International Congress of Human Genetics, a workshop of 
geneticists formulated the “Berlin Nosology” of HDCT in an attempt to resolve issues 
surrounding the nomenclature and classification of connective tissue disorders (42).  
The Berlin Nosology documented nine subtypes of EDS including EDS-III now 
referred to as EDS-Hypermobile Type.  Although recognising the disorder as an 
autosomal dominant genetic trait, the description was limited to 3 “cardinal 
manifestations”; marked articular complications, moderate dermal hyperextensibility 
and minimal scarring (42).     
 
Following the development of the “Berlin Noslogy” of HDCT the genetic basis of 
EDS was further investigated culminating in 1997 with a simplified classification 
system of the disorder, the Villefranche Criteria (15).  This new classification system 
identified 6 subtypes of EDS and provided both Major and Minor criteria to assist in 
differentiating the subtypes (Table 4).  For a diagnosis to be suggested, the presence 
of at least one major criterion is required while the minor criteria contribute to the 
diagnosis of the subtype but are insufficient in isolation to form a diagnosis of EDS.  
EDS-HT remained the only subtype without biochemical or molecular evidence 
relating to the underlying cause of hypermobility.  Generalised Joint Hypermobility, 
defined as a score of 5/9 or greater arising from using the Beighton scale, and skin 
hyperextensibility were identified as the major criteria for a diagnosis of EDS-HT 
(15) (Table 1.4). The diagnosis for EDS-HT remained reliant on clinicians’ 
interpretation of the Villefranche Criteria and subsequent physical examination in the 
absence of definitive objective tests.  The authors of the paper acknowledged the 
ongoing contention about whether EDS-HT and JHS were distinct entities or whether 
there are similar phenotypic origins for the disorders (15). 
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Evolution of JHS: 
Initial reference to Hypermobility Syndrome (HMS) reported the condition likely 
represented the extreme of normal joint mobility rather than a HDCT, representing a 
benign manifestation of GJH (1).  In 1970, Beighton and Horan suggested that the 
clinical variability in the presentation of GJH and the severity of associated 
orthopaedic complications and musculoskeletal manifestations were likely to be the 
result of different genetic traits causing abnormalities in connective tissue (12) as seen 
in HDCT.  
 
Up until the 1980’s HMS was seen as a relatively benign disorder predominately 
limited to the musculoskeletal system.  At this time, Grahame et al (1981) identified a 
range of non-musculoskeletal manifestations of the disorder including potential Mitral 
Valve Prolapse, skin thinness and fragile bones.  They additionally noted marfanoid 
habitus without diagnostic features of Marfan Syndrome in their study population 
presenting with GJH (43).  The conclusion of this paper not only referred to the 
condition as a HDCT but also challenged the perception that HMS was a benign 
condition isolated to the musculoskeletal system.   
 
Despite increasing evidence that HMS was likely a mild form of a HDCT, the initial 
Berlin Nosology in 1986 failed to specifically recognise condition as a HDCT.  
Instead “Familial Articular Hypermobility Syndrome” was documented as a 
connective tissue disorder with two subtypes – uncomplicated (i.e. GJH without 
associated orthopaedic manifestations), and the dislocating type.  This condition was 
based on the reports of Beighton and Horan, in 1973, that GJH has two subtypes, one 
associated with orthopaedic manifestations such as joint dislocations and a second 
presentation with isolated GJH.  At the time of Beighton and Horan’s findings there 
was no definitive statement that the symptomatic version of the condition was a 
separate condition to HMS (12).  This distinction was subsequently made in 1980 
when Horton et al suggested that the difference between HMS and Familial Joint 
Instability Syndrome was the absence of skin manifestations and frequent dislocations 
in the Familial Joint Instability Syndrome (44).  
 
In response to the increasing references to a multisystem disorder, the British Society 
for Rheumatology in 1991 proposed a new set of criteria for the diagnosis of HMS.   
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The criteria contained 2 major and 9 minor criteria, with a diagnosis was only 
possible if two major criteria or one major and two minor or four minor criteria were 
present in the absence of a HDCT such as Marfan Syndrome or EDS as defined by the 
“Berlin Nosology” (45).  The inclusion of mitral valve prolapse became controversial 
when Mishra et al published a study questioning the significance of bone, cardiac, 
skin and eye abnormalities in JHS.  They noted that the prevalence of mitral valve 
prolapse was not statistically significant compared to individuals unaffected by HMS 
(46).  This study prompted a review of the diagnostic criteria and the subsequent 
creation of the Brighton criteria with the deletion of mitral valve prolapse as a minor 
diagnostic criterion (16), labelling the condition Joint Hypermobility Syndrome 
(Table 1.4).  
Table 1.4 Diagnostic criteria for EDS-HT and JHS  
Villefranche Criteria for  EDS-HT (15) Brighton Criteria for JHS (16) 
Major Criteria  1. Beighton ≥ 5/9 2. Skin involvement (hyperextensibility and/or 
smooth, velvety skin) 
Minor Criteria  1. Recurring joint dislocations 2. Chronic joint or limb pain  3. Positive family history  
 
Major criteria 
1. Beighton ≥ 4/9 
2. Arthralgia for > 3 months in ≥4 joints 
Minor criteria: 
1. Beighton score 1-3/9 if  >50yrs old 
2. Arthralgia > 3 months in 1-3 joints or back 
pain >3 months 
3. Dislocation/subluxation in > 1 joint or in one 
joint on more than one occasion 
4. Soft tissue rheumatism ≥  3 lesions 
5. Marfanoid habitus 
6. Abnormal skin: striae, hyperextensibility, thin 
skin, papyraceous scarring  
7. Eye signs: drooping eyelids or myopia or 
antimongoloid slant  
8. Varicose veins or hernia or rectal or uterine 
prolapse 
Diagnosis of EDS-HT suggested when: 
One or more of the major criteria present. 
Minor criteria points differentiate between subtypes of 
EDS but are not sufficient in the absence of major 
criteria findings for a diagnosis of EDS-HT.  
JHS is diagnosed in presence of  
1. Two major criteria 
2. One major and two minor criteria  
3. Four minor criteria  
4. Unequivocally affected first degree relative 
in the absence of Marfan Syndrome or EDS (other than 
EDS-HT) 
Recognition of a single clinical entity – JHS/EDS-HT 
In 2009 the first formal acknowledgment occurred that JHS and EDS-HT are 
phenotypically the same HDCT, following the collaboration of notable Geneticists 
and Rheumatologists working in the field of HDCT (3).  It was observed that although 
there is significant overlap between the clinical presentation of JHS/EDS-HT and a 
range of HDCT, including Marfan syndrome, OI type 1 and the other subtypes of 
EDS, JHS/EDS-HT (Figure 1.2 and Table 1.5) can be identified as a distinct 
diagnosis. 
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Figure 1.2 Clinical overlap of HDCT(47)  
Table 1.5 Clinical features of HDCT(47) 
Clinical 
features 
JHS/EDS-HT Marfan Syndrome Ehlers-Danlos 
Syndrome 
Osteogenesis 
Imperfecta 
Joint Hypermobility 
Arthralgia 
Dislocations  
Instability  
Soft tissue trauma 
Hypermobility 
Arthralgia  
Dislocations 
Instability  
Soft tissue trauma 
Hypermobility  
Arthralgia  
Dislocation  
Instability  
Soft tissue trauma 
Hypermobility  
Arthralgia  
Dislocation  
Instability  
Soft tissue trauma 
Skeletal  Marfanoid habitus  
Osteopenia  
Slender extremities  
Pectus deformities  
Fracture  
Scoliosis  
Arachnodactyly 
Deformity 
Marfanoid Habitus 
Slender extremities  
Pectus deformities  
Scoliosis  
Arachnodactyly 
Osteoporosis  
Fracture  
Scoliosis  
Deformity  
Osteoporosis  
Fracture 
Deformity  
Cutaneous Hyper-extensibility  
Thinning  
Striae Atrophicae  
Papyraceous scars 
Easy bruising  
Hyper-extensibility  
Thinning  
Striae Atrophicae  
Papyraceous Scars  
Easy Bruising  
Hyper-extensibility  
Thinning  
Striae Atrophicae 
Molluscoid 
Pseudotumours 
Violaceous papyraceous 
scars  
Bruising and 
Haematoma 
 
Hyper-extensibility  
Thinning  
Striae atrophicae 
Papyraceous scars  
Easy Bruising  
Eyes  Lid Laxity 
Blue sclera 
(occasionally) 
Ectopia lentis  
Visual problems 
 Blue sclera 
Vascular Varicose veins Aortic dilatation  
Mitral valve prolapse  
Aneurysm  
Subacute bacterial 
endocarditis 
Mitral valve prolapse  
Intracranial aneurysm 
Subacute bacterial 
endocarditis  
Subarachnoid 
haemorrhage 
Mitral Valve 
Prolapse  
Subacute bacterial 
endocarditis 
 
Muscular 
laxity  
Hernia 
Rectal/uterine 
prolapse 
 Hernia  
Intestinal/bladder 
diverticula 
Rectal/uterine prolapse  
Neuromyopathy 
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Ongoing difficulties establishing single diagnosis: 
Despite the consensus that JHS and EDS-HT represent the same distinct clinical 
entity there are ongoing obstacles to the diagnosis and management of this disorder in 
clinical practice.   To date the condition continues to have two diagnostic criteria (see 
Table 1.4); the Villefranche criteria for EDS-HT and the Brighton for JHS, being 
utilised to diagnose each respective condition.  As a result, there is use of conflicting 
Beighton cut-off scores to establish an underlying diagnosis of GJH, with the 
Brighton requiring a score of at least 4/9 while the Villefranche classification for EDS 
defines the presence of GJH as a score of ≥ 5/9.  
 
Unlike other subtypes of EDS, Marfan Syndrome and Osteogenisis Imperfecta the 
diagnosis of JHS/EDS-HT remains a clinical diagnosis without a confirmed molecular 
basis for the disorder.  This has resulted in the condition remaining a diagnosis of 
exclusion contributing the extended delays in the diagnosis experienced by many 
affected by the disorder.  
  
Consistency in the use of diagnostic labels in JHS/EDS-HT continues to be an 
obstacle to recognising JHS and EDS-HT as a single phenotypic disorder.  The 
condition continues to be inconsistently referred to in literature as JHS/EDS-HT, JHS 
or EDS-HT without a title that encompasses both conditions under the same 
diagnostic label.  While the impact and potential morbidly of the disorder is likely 
underplayed in literature with the condition continuing to be referred to as “Benign 
Joint Hypermobility Syndrome” in some published literature.  The delay in 
developing a single label and diagnostic criteria for the disorder is likely contributing 
to the delay in referring to both conditions in literature as a single entity and to the 
ongoing confusion seen in clinical practice surrounding the diagnosis and recognition 
of JHS/EDS-HT as a multisystem disorder of the connective tissue. 
Epidemiology of JHS/EDS-HT: 
The true prevalence of JHS/EDS-HT in the general adult population is yet to be fully 
established.  Estimates of the overall occurrence of the condition in Caucasian 
populations have indicated that the prevalence likely ranges from 0.75% to 2% (48).  
While documented prevalence of JHS in paediatric populations, identified using the 
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Brighton Criteria have been reported to range between 4.8% to 17.6% (49, 50). 
Variations in the prevalence rate is likely to relate to racial and age differences that 
have previously been identified as contributing to the variation in the expression of 
GJH in different population and age groups.  There is considerably more data 
referencing the populations presenting with symptomatic GJH without a specific 
diagnosis compared to research focusing on study populations with a clear diagnosis 
of JHS/EDS-HT in the adult and paediatric populations affected by this disorder.  
Symptomatic GJH has been reported to have a prevalence rate of 0.3% in a New 
Zealand study population ≥ 5 years of age (both Maori and Caucasian ethnicities) 
(24). While GJH associated with musculoskeletal symptoms in Greek and Indian 
paediatric samples has been documented to range from 1.7% to 15.4% (51, 52).    
 
Despite the lack of prevalence data relating to JHS/EDS-HT in the adult population, 
the condition has been identified in up to 33% of patients seeking medical care for 
gastrointestinal complaints (53) while JHS has been identified in 45% of new referrals 
to rheumatology clinics (54). The over-representation of JHS/EDS-HT patients in 
both rheumatology and gastroenterology clinics highlights the potential for significant 
morbidity associated with the disorder.   
Clinical characteristics of JHS/EDS-HT  
The clinical presentation of JHS/EDS-HT is variable, the features of the condition that 
form the basis of the diagnosis focus on the presence of arthralgia, musculoskeletal 
and cutaneous manifestations of the disorder.  In addition to these features, 
individuals affected by the disorder can present with a range of systemic 
manifestations including but not limited to urogenital, gastrointestinal, cardiovascular, 
neurological and psychological features (9) (Figure 1.3).  The presence and 
combination of pain, musculoskeletal, cutaneous and systemic features, described 
below, contribute to disease morbidity (7) with associated reduction in participation in 
activities of daily living, low levels of physical activity, significantly impaired overall 
quality of life (5) and resultant disability (6). 
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Figure 1.3 Frequency of reported manifestations of JHS (55) 
 
Musculoskeletal manifestations of JHS/EDS-HT: 
Musculoskeletal (MSK) manifestations of JHS/EDS-HT underpin the diagnostic 
criteria for both JHS (16) and EDS-HT (15).  Historically MSK and cutaneous 
features were identified as the predominant manifestations of JHS/EDS-HT with little 
recognition of the systemic co-morbidities associated with the condition (56).  MSK 
symptoms such as joint hypermobility, joint pain and recurrent dislocations have been 
reported to occur in up to 79% of individuals prior to 18 years of age, while 99% of 
individuals with a diagnosis of JHS/EDS-HT report symptoms that relate to the MSK 
system (9).  Development motor delays have been reported in the paediatric 
populations affected by JHS/EDS-HT with 21.4% found to have motor delay or 
clumsiness (57), reduced coordination paediatric (36%) (58) and delay in the onset of  
walking  of greater than 15 months (58). Symptoms relating to the MSK system are 
typically the manifestation of the disorder that prompts an individual to seek 
professional advice and management for their hypermobility with JHS/EDS-HT 
accounting for over 45% of referrals to rheumatology clinics (54).  The prevalence 
and types of MSK manifestations associated with of JHS/EDS-HT can be found in 
Table 1.6. 
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Table 1.6 MSK manifestations related to JHS/EDS-HT 
MSK Manifestation of JHS/EDS-HT Prevalence  
Hypermobility – Childhood 100% (59) 
Residual Hypermobility -  Adult 65% (59) 
73.8% (57) 
97% (60) 
Arthralgia / Joint pain 100% (61) 
83.3% (57) 
95.2% (59) 
74% (Paediatric populations) (58) 
Joint locking 11.1% (61) 
Joint dislocation 96.3% (61) 
73.8% (Recurrent Dislocations) (57) 
85.7% (59) 
Joint swelling 3.7% (61) 
38% (paediatric) (58) 
Muscular pain  29.6% (61) 
85.7% (Recurrent) (57) 
76.2% (Recurrent/Chronic) (59) 
Tendinitis   25.6% (61) 
Soft tissue lesions  42.8% (≥ 3 lesions) (57) 
Muscle weakness 14.8% (61) 
77% (60) 
 
Pain:  
Musculoskeletal pain has long been acknowledged as a significant feature of 
JHS/EDS-HT, with polyarthralgia (>3 months) constituting a major criterion for the 
diagnosis of JHS using the Brighton scoring system (16) and chronic joint or limb 
pain constituting a minor criterion for the diagnosis of EDS-HT using the 
Villefranche Criteria (15).  With progression of knowledge, the prevalent systemic 
features of JHS/EDS-HT including neuropathic, visceral, headache and dysfunctional 
pain in addition to pain arising from the musculoskeletal system have been recognised 
(62) (Figure 1.4). 
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Figure 1.4 Factors contributing to pain in EDS (62) 
 
Pain relating to the musculoskeletal system is a frequently reported manifestation of 
JHS/EDS-HT with joint pain identified as having the greatest impact on overall 
quality of life when compared to all other self-reported manifestations of the disorder 
(9).   Chronic pain has been documented to affect up to 100% of individuals with a 
diagnosis of JHS/EDS-HT (63), while 85.7% report experiencing progressively 
worsening pain (63).   Musculoskeletal pain is typically widespread affecting multiple 
joints, with a study investigating pain in EDS-HT reporting the mean number of joints 
affected as 8.9, while the intensity of pain experienced by individuals with a diagnosis 
of EDS-HT was reported as 5.3/10 on a Visual Analogue Scale (VAS) (63).   Similar 
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results were found in another sample of EDS-HT patients (N=162), with 98% of 
participants experiencing pain, the mean of which was reported as 49.1/100 with 91% 
of participants using analgesia.  The severity of pain and the number of patients 
reporting pain (p ≤ 0.001 for both) was significantly greater for the hypermobile than 
vascular subtype of EDS (60).  The prevalence of pain (p < 0.001) and the most 
severe pain experienced (p = 0.014) was also significantly greater in the hypermobile 
compared to the classical subtype of EDS (60).   The mechanisms behind 
musculoskeletal pain are thought to relate to both acute tissue micro-trauma, caused 
by repetitive subclinical articular damage related to joint instability, and to soft tissue 
injuries, joint subluxation and dislocations and the progression to widespread non-
specific pain, all of which likely contribute to the development of chronic pain over 
time (62, 64).   Other factors which play a role in the development and maintenance 
of chronic pain include; kinesiophobia (57) and subsequent deconditioning, 
significant fatigue, reduced quality of life and functional capacity.   Figure 1.5 
demonstrates a model hypothesized to explain the pathogenesis of chronic pain in 
JHS/EDS-HT (65). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Hypothesized pathogenesis of chronic pain (65) 
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Pain identified as being neuropathic in origin has been reported to affect between 50% 
(66) and 68% (67) of individuals with JHS/EDS-HT, challenging the historical beliefs 
that pain experienced in JHS/EDS-HT is predominately musculoskeletal in origin.  
The underlying mechanisms of neuropathic pain, is thought to relate to axonal and 
compressional neuropathies related to repeated subluxations and dislocations of joints 
and nerves (62).  Small fibre neuropathy has also been identified in a cohort of EDS 
subjects, JHS/EDS-HT accounting for 83% of the sample, finding all participants had 
symptoms of neuropathic pain and associated small fibre neuropathy (68).  
 
Central sensitization, evidenced by the presence of significantly lower pain pressure 
thresholds in EDS-HT compared to unaffected control subjects has been proposed as 
a potential mechanism behind the progression to chronic wide-spread pain in EDS-HT 
(66).  Generalised hyperalgesia characterized by widespread reduced pain pressure 
thresholds in regions unaffected by pain has been linked to chronic pain states such as 
fibromyalgia and chronic back pain (66).  The documentation of this phenomenon in 
EDS-HT, provides evidence that generalized secondary hyperalgesia may play a role 
in the development of widespread chronic pain in this population. 
 
Cutaneous manifestations: 
Cutaneous manifestations of JHS/EDS-HT are features frequently associated with the 
condition, with elements well recognized as pivotal signs requiring evaluation when 
diagnosing either JHS or EDS-HT.  Skin manifestations which have been linked to 
JHS/EDS-HT include striae (stretch marks), typically wide and atrophic, delayed 
healing associated with the development of atrophic scars (48), skin laxity or hyper-
extensibility,  skin fragility, easy bruising and piezogenic papules (59) (Figure 1.6).  
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Figure 1.6 Cutaneous manifestations of JHS/EDS-HT:  
Top Left – skin hyper-extensibility; Top Right – Papyraceous scaring; Bottom Left – Stria 
atrophicae; Bottom Right: Piezogenic papules. 
 
The descriptions of cutaneous manifestations of JHS and EDS-HT accentuate the 
clinical overlap between this condition, other subtypes of EDS and a number of 
HDCT. Both the Villefranche criteria for EDS-HT, and the Brighton criteria for JHS, 
reference skin hyper-extensibility.  However, discrepancy exists when considering 
other cutaneous manifestations of JHS and EDS-HT.  The Brighton criteria records 
striae, thin skin and abnormal scarring (15), previously described as atrophic (48), as 
minor criteria for the diagnosis of JHS. Smooth, velvety skin features as a major 
criterion together with skin hyper-extensibility for the diagnosis of EDS-HT, however 
the Villefranche criteria notes the presence of atrophic scars associated with of GJH 
as suggestive of the classical subtype of EDS not EDS-HT (15).   
 
The clinical evaluation of cutaneous manifestations of JHS/EDS-HT creates 
additional impediment when attempting to uses these signs objectively in the 
diagnosis of JHS/EDS-HT, as there is no universal method for assessing these 
features.  Attempts to standardize the testing protocol for these features have the 
demonstrated potential for inter-rater reliability to be substantial in the assessment of 
skin extensibility and bruising, and good for scarring (69).  However, testing for skin 
consistency or quality (i.e. thin/velvety or smooth) was only fair when using a 
standardized testing protocol (69).  As a result, the authors suggested excluding skin 
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consistency from the diagnostic criteria for JHS/EDS-HT and recommend setting an 
upper limit for normal skin extensibility to 3cm to improve diagnostic accuracy (69).   
 Systemic Manifestations of JHS/EDS-HT: 
Recognition of the types and significance of non-MSK related manifestation of 
JHS/EDS-HT has increased considerably over the past 3 decades.  Non-
musculoskeletal manifestations have been reported to affect up to 95% of individuals 
with JHS/EDS-HT (70).  Non-MSK manifestations of JHS/EDS-HT have been 
reported to affect nearly all body systems and include, cardiovascular, 
gastrointestinal, psychological, severe fatigue, neurological and genitourinary systems 
(9).  Despite increasing reference in the literature to the systemic symptoms and signs 
of JHS/EDS-HT challenges continue to exist in the recognition of the condition as a 
complex systemic condition (56, 71).  
 
Cardiovascular Manifestations: 
A range of cardiovascular conditions have been linked to the presence of JHS/EDS-
HT including structural, electrophysiological and orthostatic intolerance.  Autonomic 
dysfunction is thought to play a role in symptoms related to orthostatic intolerance. 
Early literature described catastrophic vascular complications related to EDS 
including arterial dissections and aneurysms, electrocardiographic abnormalities, 
congenital abnormalities, and cardiac valve disorders (72).  These studies were 
conducted prior to the development of the Villefranche Criteria and reported on 
participants with undifferentiated subtypes of EDS.  Since the development of the 
Villefranche and Brighton criteria the prevalence, type and severity of cardiovascular 
manifestations associated with JHS/EDS-HT have been better defined.  
 
Structural abnormalities associated with the presence of JHS/EDS-HT include 
tricuspid, mitral and aortic valve disorders and aortic root enlargement (73).  There 
has been contradictory evidence to support an increased rate of mitral valve prolapse 
(MVP) compared to the general population, with the initial inclusion of the condition 
in the diagnostic criteria for JHS.  MVP was subsequently removed from the revised 
Brighton Criteria following the finding of no statistical significance between the 
presence of MVP in a population affected by JHS (10%) compared to a healthy 
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control sample (7%) (46). Despite the deletion of MVP from the diagnostic criteria 
for JHS the prevalence of MVP documented in this population continues to vary 
widely, ranging from 0% (73) to 79% (74) .  Potential reasons accounting for the 
variation in the reported prevalence of MVP in JHS/EDS-HT studies include the use 
of small sample sizes (<30 participants) (74-76), use of varying criteria to diagnose 
MVP (46) and changes and improvements in sonographic technology utilized (M-
Mode compared to two dimensional echocardiogram) (75).  Electrophysiological 
abnormalities relating to cardiac function at rest have shown significant increase in 
PR interval and P wave duration in those with EDS-HT compared to healthy control 
subjects (75).  
 
Orthostatic intolerance is a significant non-musculoskeletal complaint associated with 
JHS/EDS-HT with a reported prevalence ranging from 74% (77) to 78% (78).  
Postural Orthostatic Tachycardia Syndrome (POTS) is the most frequently reported 
form of orthostatic intolerance in this population, its prevalence ranging from 15% 
(78) to 41% (77).  POTS is clinically diagnosed, in the absence of any other chronic 
debilitating illness, when ongoing symptoms of orthostatic intolerance (Table 1.7), are 
present for more than 6 months and associated with an increase in heart rate of  ≥ 
30beats/min or a heart rate of > 120 beats per minute within 10mins of assuming an 
upright posture or undergoing the Head Up Tilt Test (HUTT) (79).   In addition to 
POTS, between 22% (78) and 26% (77) of individuals experience orthostatic 
intolerance caused by orthostatic hypotension in response to upright postures, which 
is defined as a sustained reduction in systolic blood pressure of > 20mmHg or 
>10mmHg of diastolic blood pressure within 3 min of assuming an upright posture or 
HUTT (79) .   
 
Orthostatic intolerance is linked to a range of symptoms including dizziness, fatigue, 
orthostatic palpitations, exercise intolerance, headache, reduced concentration, near 
syncope and syncope (Table 1.7). These symptoms are typically preceded by 
orthostatic changes and can be exacerbated by physical exertion and heat (80).  
 
Although the exact mechanisms behind orthostatic intolerance in JHS/EDS-HT is yet 
to be established it is thought to relate a complex interplay between autonomic 
nervous system dysfunction, connective tissue laxity, deconditioning, depression and 
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pain induced sympathetic arousal (77).  The likely mechanism of dysautonomia 
associated with EDS-HT related orthostatic intolerance has been supported by 
evidence of higher resting systolic and diastolic blood pressure and heart rate in 
individuals with EDS-HT compared to control subjects suggestive of increased 
sympathetic activity at rest (77).  In addition, tests for autonomic reactivity have 
shown individuals with EDS-HT have reduced sympathetic response to acute 
challenges to the cardiovascular system (such as the HUTT and valsalva manouvres) 
(77, 78) with reactions to testing suggestive of insufficient sympathetic 
vasoconstriction. Neuropathic mechanisms such as impaired peripheral sympathetic 
nerve function have been supported by findings of decreased sweat response, when 
testing the quantitative sudomotor axon reflex test, in patients with EDS-HT 
potentially contributing to orthostatic intolerance (77).  The potential influence of 
connective tissue laxity to orthostatic intolerance has been demonstrated by the 
association between higher Beighton scores and lower resting blood pressure and 
higher heart rate on othostatic challenge, suggestive of reduced peripheral vascular 
resistance contributing to venous pooling during upright positioning (77).  Skin laxity 
has been identified as predictive of sympathetic dysfunction in EDS-HT (77).  The 
suggestion that deconditioning plays a role in orthostatic intolerance in JHS/EDS-HT 
through changes such as reduced plasma volume and changes to baroreflex buffering 
and adrenoreceptor sensitivity is yet to be confirmed (77, 78, 81). 
 
Table 1.7 Features of Orthostatic Intolerance in JHS/EDS-HT 
Symptom related to Orthostatic Intolerance: Prevalence of symptoms of Orthostatic 
Intolerance in JHS/EDS-HT  
Dizziness 58% (82) 
88% (78) 
Fatigue 58% (82) 
67% (central) (78) 
71% (physical) (78) 
Orthostatic Palpitations 54% (82) 
90% (78) 
Near syncope 58% (82) 
83% (78) 
Syncope 56% (78) 
62% (82) 
Headache/migraine 73% (82) 
75% (78) 
Impaired concentration 71% (78) 
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The autonomic symptom burden associated with EDS-HT is significantly greater 
compared to both the classical and vascular subtypes of EDS and comparable to the 
autonomic symptom burden in observed in fibromyalgia (81).  When autonomic 
symptoms related to JHS are divided into three categories, (pre)syncope, 
cardiorespiratory and gastrointestinal, the presence of all three symptom categories is 
associated with a 3 times higher incidence of fatigue compared to individuals not 
affected by JHS (55).  Fatigue has also been linked to a specific diagnosis of POTS, 
with reports of up to 58% of individuals with JHS-related POTS suffering from 
clinically significant fatigue (82), while 95% of all individuals diagnosed with POTS 
report fatigue associated with the disorder (83).   
 
Genitourinary manifestation:  
Genitourinary manifestations and obstetric complications have been associated with 
JHS/EDS-HT (Table 1.8) and may occur at a younger age in this population 
compared to the general population.   The prevalence of urinary incontinence 
affecting women with the condition has been reported to range from 42.1% (84) to 
73.3% (85), while 26% of children diagnosed with JHS have reported frequent 
urinary incontinence (86).   Despite the majority of affected women rating the leakage 
of urine as small, over half of these women reported that it severely affected their 
QoL compared to only one third of unaffected women who also experience urinary 
incontinence (87).  In the pediatric population incontinence was also found to be a 
predictor of poor HRQoL (86).  
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Table 1.8 Genitourinary manifestations of JHS/EDS-HT: 
Genitourinary Manifestation Study Sample characteristics Findings 
Incontinence: Arunkalaivanan et al 
2009 (88) 
148 adult female individuals 
with BJHS 
• 68.9% reported urinary incontinence (stress or urge incontinence) 
• 14.9% Fecal incontinence  
 
Jha, Arunkalaivanan and 
Situnayake 2007 (87) 
30 Female individuals with 
BJHS  
Mean age 40yr 
 
30 Control  
Mean age 36yrs 
• 60% urinary incontinence in BJHS compared to 30% experiencing urinary 
leakage in control  
• 67% of BJHS with urinary incontinence rated amount of leakage as small  
• 55% in BJHS compared to 33% of control individuals who experienced 
incontinence reported severely affected QOL 
 
Mastoroudes et al 2013a 
(85) 
60 female individuals with 
BJHS  
 
60 control participants  
 
Mean 39.4yrs  
• 73.3% of prevalence of urinary incontinence in BJHS group compared to 
48.3% 
• 62% BJHS compared to 38.3% in control reported urge incontinence  
• 63.3% compared to 36.7% stress incontinence  
Urinary manifestations with significantly greater frequency compared to 
control (p < 0.05): 
• Urinary frequency  
• Nocturia  
• Nocturnal enuresis  
• Intercourse related incontinence  
• Urinary tract infections  
• Bladder pain 
• Urge incontinence  
 
McIntosh et al 1995 (84) 36 female participants with 
EDS (type I, (II and III) 
Mean age40.3yrs 
 
19 EDS-III  
Mean age 38.3yrs 
• 52.8% of participants experienced Incontinence  
• 42.1% of EDS-III reported incontinence, with stress incontinence 
accounting for 84.6% of incontinence type.  
Prolapse: Mastoroudes et al 2013b 
(89) 
60 Female participants with 
BJHS 
60 Control participants  
 
Mean age 39.4 
Pelvic organ prolapse (POP): 
• 73.3% of BJHS participants had a clinically significant POP compared to 
35% of control subjects.  
 
Vaginal bulge symptoms increase prevalence in BJHS compared to control: 
• Heaviness or dragging from the vagina or lower abdomen as day goes on 
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(28.3%) 
• Discomfort in vagina (25%) or back (60%)worse when standing and eased 
by lying  
• Backache worsen vaginal discomfort (36.7%) 
 
POP symptoms in BJHS associated with significantly worse QOL compared to 
control.  
 
McIntosh et al 1995 (84) 36 female participants with 
EDS (type I, (II and III) 
Mean age40.3yrs 
 
19 EDS-III  
Mean age 38.3yrs 
Prolapse: 
• 25.9% of all EDS participants  
• 33.3% of EDS-III participants 
Obstetric complicaitons: Morales-Rosello, 
Hernandez-Yago and 
Pope 1997 (90) 
Case review – Pregnancy 
related published cases of 39 
EDS-III Females 
• 15% preterm delivery/premature rupture of membranes 
• 10% Gestational intrapartum haemorrhage  
• 5%  post partum haemorrhage  
• 82% live born  
Lind and Wallenburg 
2002 (91) 
Retrospective study – 46 
women with EDS, 128 
pregnancies 
 
43 pregnancies of 33 
unaffected women (control) 
 
33% EDS-III 
• Pelvic pain and instability 26% in affected individuals compared to 
control 7%  
• Preterm delivery 21% compared to 40% unaffected control 
• Post partum haemorrhage 19% compared to 7% control  
• Complicated perineal wounds 8% in EDS compared to 0% in control 
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Obstetric complications relating to antenatal pelvic pain, post-partum hemorrhage and 
complicated wound healing have been shown to have higher rates of occurrence in 
women affected by all subtypes of EDS compared to the general community (91).  
There have also been reports of varicose veins, hernia, antenatal hemorrhage (92) and 
preterm labour/premature rupture of membranes (90, 92) associated with both EDS-
HT and other subtypes of EDS.  There are, however, few large studies investigating 
the prevalence of obstetric complications in JHS/EDS-HT compared to that found in 
the general community. 
 
The presence of pelvic organ prolapse in JHS/EDS-HT has been reported to vary from 
19% (59), in self report questionnaires, to 73.3% of women formally assessed with 
questionnaires and physical examination (89).  This suggests study participants may 
under report or fail recognize the condition or its symptoms  
 
Gastrointestinal manifestations:  
Significant and catastrophic gastrointestinal manifestations associated with EDS have 
been recognized and recorded in the literature since the mid 1900’s with initial reports 
of gastrointestinal complications relating to EDS focused on rare events such as 
spontaneous intestinal perforation and significant gastrointestinal hemorrhage (93).  
In 1969, Beighton, Murdoch and Votteler described structural gastrointestinal 
abnormalities associated with EDS as occurring more frequently and being associated 
with less morbidity and mortality. These abnormalities included external hernia 
(femoral, inguinal and umbilical), eventration of the diaphragm, rectal prolapse and 
diverticular disease of the colon (93).  With the identification of clearer subtypes of 
EDS using the Villefranche criteria, knowledge relating to the risks associated with 
catastrophic gastrointestinal complications in JHS/EDS-HT has become better 
understood.   It is now recognized that gastrointestinal perforations and hemorrhage 
almost exclusively occur in the vascular subtype of EDS, however JHS/EDS-HT has 
been linked with a range of structural and functional gastrointestinal symptoms 
associated with disease morbidity and quality of life (53) (Table 1.9).   It has been 
estimated that up to 33% of individuals seeking tertiary care for gastrointestinal 
symptoms fulfill the Brighton criteria and have undiagnosed JHS (94). 
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Table 1.9 Frequently reported gastrointestinal symptoms in JHS/EDS-HT 
Gastrointestinal manifestations Prevalence in JHS/EDS-HT(%) 
Dysphagia  • Adult 14.3% (95) 
• Adult 11.1% (96) 
Dyspepsia/gastritis • Adult 14.3% (95) 
• <10years of age 8% (97) 
• >40years of age 48% (97) 
• Adult 10.7% (96) 
Postprandial fullness  • Adult 41.4% compared to control 27.1% 
(94) 
• Adult 7% (96) 
Gastro-oesophageal Reflux Disease 
(GORD)/Heartburn 
• Adult 52.4% (95) 
• Adult 33% (compared to 23.5% control) 
(94) 
• < 10 years of age 57.1% (97) 
• > 40 years of age 74% (97) 
• Adult 57.1% (59) 
• Adult 38% (96) 
Bloating • Adult 57.1% (95) 
• Adult 17% (96) 
Nausea  • Adult 57.1% (95) 
• Adult 44.3% (96) 
Vomiting  • Adult 57.1% (95) 
• Adult 24.7% (96) 
Recurrent Abdominal Pain • Adult 76.2% (95) 
• < 10 years of age 26% (97) 
• > 40 years of age 68% (97) 
• Adult 61.9% (59) 
• Adult 56.1% (96) 
Abnormal colorectal transit • Adult 100% (95)  
Constipation/diarrhea  • Adult 76.5%  (95) 
• < 10 years of age 54% (97) 
• > 40 years of age 72% (97) 
• Adult 33.3% (59) 
• Adult constipation 42.4% (96) 
Abdominal hernia  • <10 years of age 10% (97) 
• >40 years of age 20% (97) 
• Adult 4.8% (59) 
 
Structural abnormalities of the gastrointestinal tract, previously linked to JHS/EDS-
HT, include hernias (59, 93); hiatus, inguinal, femoral and umbilical, megalocolon 
(abnormally wide colon) (98), dolichocolon (abnormally long colon) (59), diverticula 
of the colon (59, 93, 96), orthostatic recurring visceroptosis (98) rectocele (96) and 
rectal prolapse (93).  In addition to structural gastrointestinal manifestations recent 
research has suggested that patients with JHS are more likely to be diagnosed with 
functional gastrointestinal disorders (FGID) compared to organic disorders when 
seeking diagnosis of gastrointestinal symptoms at a tertiary gastrointestinal clinic. The 
prevalence of diagnosed JHS has been identified as significantly greater in FGID 
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patients (39%), compared to patients diagnosed with an organic gastrointestinal 
condition (27.5%) (99).  Although JHS was more prevalent in FGID, organic 
disorders were frequently diagnosed in individuals with JHS, accounting for 38.6% of 
individuals diagnosed with reflux disorders, 21% of ulcerative colitis cases and 32% 
of individuals diagnosed with Crohn’s disease (99).    
 
FGID can be defined as intermittent or chronic gastrointestinal symptoms, which are 
not explained by a pathophysiological, biochemical or structural cause (95, 100).  In 
JHS/EDS-HT, symptoms related to FGID where no structural diagnosis have been 
found include; bloating, nausea, vomiting, reflux, recurrent abdominal pain, 
constipation, dysphagia, and diarrohea.  In a 20yr retrospective study of individuals 
affected by EDS-HT, 30.3% reported symptoms consistent with irritable bowel 
syndrome (96). Symptoms not explained by the current pathophysiological 
understanding of gastrointestinal manifestations in JHS/EDS-HT are referred to as 
FGID.   The role of a dysfunctional autonomic nervous system and the effect of 
altered connective tissue on the gastrointestinal system in JHS/EDS-HT are not yet 
fully understood.   It is therefore possible that with increasing research and knowledge 
developing in this area, the exact mechanisms and pathophysiology behind currently 
unexplained gastrointestinal manifestations in JHS/EDS-HT may become clearer.  
 
Gastrointestinal dysmotility has been associated with JHS/EDS-HT, with reports of 
altered gastric emptying and colonic transit showing both accelerated and delayed 
patterns of motility (96). This was supported by a study conducted by Zarate et al in 
2010 in which 80% of individuals assessed for gastric emptying (15) showed delay 
while 100% of individuals assessed for colorectal transit (5) showed signs of 
abnormal transit (95).  
 
Lifetime gastrointestinal symptom profile in JHS/EDS-HT has demonstrated that 
symptoms such as dyspepsia, recurrent abdominal pain, Gastro-oesophageal Reflux 
Disease (GORD) and constipation increase in frequency as an individual ages (97).  
The severity of JHS/EDS-HT presentation is associated with increased upper and 
lower GI tract symptoms, with lower GI tract symptoms related to both chronic pain 
and autonomic symptom burden (94).   
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Fatigue: 
Fatigue is a subjective multifactorial complaint experienced by both healthy 
individuals and by those affected by a range of health conditions.  The presentation of 
fatigue can be mediated by medical or psychological factors and may result from side 
effects caused by the medical management of many diseases.  The experience of 
fatigue can be described as a sense of overwhelming tiredness or exhaustion or feeling 
of lacking in energy, distinct from muscle fatigue or weakness (101). It can present in 
an acute form as a physiological response, or as a consequence or manifestation of a 
chronic condition.  Severe debilitating chronic fatigue is frequently associated with a 
range of systemic medical conditions including but not limited to Multiple Sclerosis 
(102), Rheumatoid Arthritis (103) and Systemic Lupus Erythematosus (104).   
 
Due to the subjective nature of fatigue, fatigue severity is typically assessed using 
questionnaire-based tools.  Research investigating JHS/EDS-HT have utilized the 
Fatigue Severity Scale (FSS) (57) while general EDS research have employed the 
Checklist Individual Strength (CIS) (60, 105) to measure fatigue severity, providing 
comparative data for both tools in this population. The FSS is a 9 item self-report 
questionnaire, with the FSS mean fatigue severity individual item score of 4 out of a 
possible 7 (106) or total score of 36/63 (102), generally accepted as the cut-off 
indicating the presence of significant fatigue.  The CIS questionnaire measures 4 
aspects of fatigue (subjective feelings of fatigue, motivation, physical activity and 
motivation) (105), with the fatigue severity determined using the CIS-Fatigue 
subscale. This subscale includes 8 items with possible scores ranging from 8 to 56.  
The CIS cut-off for the CIS-Fatigue subscale score is ≥ 35/56 which represents a 
score two standard deviations higher than the mean of healthy individuals (107).  
 
Current research reports fatigue to be one of the most debilitating symptoms 
experienced across all subtypes of EDS (8, 105, 107) and has been associated with 
decreased muscle strength (105), sleep disturbances, concentration problems, 
impaired social functioning, pain severity and lower self-efficacy (107).   The 
prevalence of severe fatigue is greater in the EDS-HT subtype than in the classical 
subtype of the condition (107) (Table 1.10). Interestingly despite the highest rates of 
severe fatigue being reported by people with the EDS-HT subtype compared to all 
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subtypes of EDS, the Villefranche criteria references fatigue as a frequent complaint 
in only the classical subtype of EDS but not EDS-HT (15).   
 
The incidence of severe fatigue in JHS/EDS-HT has been reported in the literature as 
ranging from 82 to 100% (9, 108) with the variance in reported incidence likely 
related to study design and patient selection, the screening tool used to ascertain 
fatigue severity and the participant comorbidities (Table 1.10). A large cross-sectional 
study investigated the disease profile of EDS-HT (9), establishing chronic fatigue as 
the manifestation participants ranked as having the 2nd highest impact on their quality 
of life, the 6th most frequent feature of the condition and the 2nd most commonly 
reported systemic feature of the disorder (9).    
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Table 1.10 Prevalence of Fatigue in JHS/EDS-HT 
Study Sample characteristics Prevalence of Fatigue  
(%) 
Associated Findings Conclusions 
Rowe et al 1999 (108) 12 participants (6 EDS-HT, 
6 Classical EDS) 
11 female 
Median age 15.5yrs 
100% Fatigue > 6 
months 
 
 
100% met criteria for CFS 
 
Orthostatic Testing: 
• 9/12 had neurally mediated Hypotension 
•  7/10 POTS in first 10min of upright posture 
• 3/10 Isolated POTS 
Focus of paper was 
associations between CFS 
and orthostatic intolerance.  
Not JHS/EDS-HT specific. 
Castori et al 2010 (59) 21 participants (EDS-HT) 
18(85.7%) Female  
3(14.3%) Male 
Mean age 34.8yrs 
85.7% Chronic 
asthenia fatigue  
 Small cohort of patients.  
EDS-HT specific.  
Voermans et al 2010a (60) 273 Participants EDS: 
• 162 EDS-HT  
• 45 Classic EDS 
• 11 Vascular EDS 
• 2 Kyphoscoliotic EDS 
• 53 Type unknown.  
 
Mean age 41yrs 
92% of participants 
reported chronic 
fatigue > 1yr  
 
Checklist Individual 
Strength (CIS) fatigue 
subscale. 
 
Multiple regression analysis – Pain and Fatigue 
predictors of Functional Impairment in all EDS 
patients  
R2 = 0.309  
 
Concluded pain should be a 
focus in symptomatic 
management of EDS.  
No suggestions regarding 
fatigue.  
Voermans et al 2010b (107) 273 Participants EDS: 
• 162 EDS-HT  
• 45 Classic EDS 
• 11 Vascular EDS 
• 2 Kyphoscoliotic EDS 
• 53 Type unkown.  
 
Mean age 40.7yrs 
Severely Fatigued 
using the CIS: 
• Total cohort 77% 
• EDS-HT 84%  
• Classic EDS 69% 
 
 
Statistical significant difference between the 
presence of severe fatigue in EDS-HT and Classical 
EDS subtype. 
 
Multiple regression analysis for determinants of 
fatigue (R2 = 0.382): 
• Sleep disturbances  
• Concentration problems  
• Social functioning and social support 
• Self-efficacy concerning fatigue 
• Pain  
 
40% of sample – fatigue had greater impact on 
QOL compared to pain measured using Short 
Form-36 
 
Suggested addressing 
predictors of fatigue in the 
symptomatic management of 
individuals with EDS.  
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Voermans et al 2011 (105) 30 participants EDS  
• 17% EDS-HT 
Mean age 30  
53% Severely fatigued 
using the CIS Fatigue 
score 
Multiple regression analysis for predictors of 
fatigue severity (R2 adjusted 0.27) 
• Pain severity VAS 
• Number of muscles with weakness on 
dynamometry 
 
Pain and reduced muscle 
strength associated with 
increasing fatigue severity.  
No association found 
between muscle weakness 
and physical activity.  
 
Suggested future longitudinal 
studies with quantitative 
measures of physical 
activity.  
Celletti et al 2012 (109) 11 participants EDS-HT 
Mean age 43.08yrs 
Nil % documented Significantly higher Mean Fatigue Severity Scale 
(FSS) individual scores compared to controls (6.2 ± 
0.9 versus 2.3 ± 0.7; p > 0.05) 
Inverse correlation on gait analysis found between 
vertical Ground Reaction Force (GRF) and Fatigue 
severity i.e. decreasing vertical GRF with 
increasing fatigue severity.  
Authors hypothesized 
reduced GRF may be a 
consequence of reduced 
proprioceptive acuity.  
 
Suggested further evaluation 
of predictors of fatigue 
(identified by Voermans et al 
2010b) to determine cause or 
consequence relationship 
between fatigue and identify 
determinants of fatigue.  
Celletti et al 2013(57) 42 Participants JHS/EDS-
HT 
95.2% female  
Mean age 32.8yrs  
 
88.1% Chronic Fatigue 
  
Mean FSS score 5.47 ± 1.97 
 
Strong correlation between general fatigue severity 
and kinesiophobia.  
 
Authors proposed a three-
phase model of “pain-
kinesiophobia-fatigue” 
whereby musculoskeletal 
pain leads to fear of 
movement causing fatigue 
due to bodily disuse.  
 
Suggested individualized 
multidisciplinary 
rehabilitation programs to 
address and prevent chronic 
pain and deconditioning.  
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Murray et al 2013 (9) 466 Participants EDS-HT 
90% Female  
Age not stated 
82% of participants 
reported chronic 
fatigue 
Chronic fatigue was the 2nd most frequent Non-
MSK manifestation of EDS-HT and was ranked 6th 
compared to all reported features of the condition.  
 
Chronic fatigue was rated by participants as having 
the highest impact of all non-MSK manifestations 
of EDS-HT and having the 2nd highest impact on 
QoL of all reported features of the disorder. 
Emphasized the complexity 
of EDS-HT, with the clinical 
presentation not limited 
manifestations relating to 
joint hypermobility or 
cutaneous features. 
 
Agreed with previous 
authors that there is a need 
for improved recognition and 
management of the condition 
as a multisystem disorder.  
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To date there have been only limited studies (57, 109) with small sample sizes, that 
have focused on investigating fatigue specifically affecting adult individuals 
diagnosed with EDS-HT, with larger studies investigating fatigue by recruiting 
individuals with all subtypes of EDS (60, 107).   Fatigue severity has been identified 
as a potential predictor of functional impairment in EDS (60).   While two studies 
have attempted to determine the potential determinants of fatigue severity in the EDS 
population (105, 107) (Table 1.10).  A small study of EDS participants (17% EDS-
HT) identified that pain and muscle weakness determined 27% of fatigue severity 
variance (105).  A larger study (59% EDS-HT) identified that sleep disturbances, 
concentration problems, level of social functioning and level of social support, self-
efficacy concerning fatigue and reported pain predicted 38% of the fatigue severity 
(107).  
 
Particularly in JHS/EDS-HT there is a paucity of research attempting to define the 
mechanism behind fatigue severity and to identify the predictors of this significant 
manifestation of the condition.  Further specific investigation in this area is likely to 
progress the knowledge and improve the assessment and management strategies for 
severe fatigue in JHS/EDS-HT. 
 
Psychological manifestations: 
Psychological comorbidities in GJH have been thoroughly investigated and links 
drawn between joint hypermobility and a range of psychological conditions including 
anxiety, phobias, depression and somatosensory amplification (Table 1.11).   The true 
incidence and range of psychological manifestations affecting individuals with a 
definite diagnosis of JHS/EDS-HT is not as well defined.  Definitional issues relating 
to the use of the term Joint Hypermobility Syndrome in Psychiatric literature have 
occurred with numerous authors using the term Joint Hypermobility 
Syndrome/Benign Joint Hypermobility Syndrome to describe individuals presenting 
with GJH as identified using the Beighton criteria (110).   This terminology is at odds 
with the nomenclature recognized by the Rheumatology and Genetics community to 
describe symptomatic joint hypermobility with systemic manifestations, in the 
presence of connective tissue disorders as in the case of JHS/EDS-HT.   
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Table 1.11 Psychiatric research referring to GJH as “JHS”,   
Study Sample characteristics Assessment method Evaluated for JHS 
using Brighton 
Criteria 
Diagnosis (JHS or 
GJH) based on  study 
methodology 
Results  
Bulbena et al 1988 (111) 
* 
112 subjects “JHS” – 
sampled from 
Rheumatology Clinic  - 
joint pain 
50 Controls 
 
Beighton score  
 
No  GJH • 75.9% Anxiety  
• 36% Simple phobia 
• 27% Agoraphobia 
Bulbena et al 1993 (112) 
** 
114 subjects “JHS” 
Rheumatology Clinic – 
joint pain 
59 Control subjects 
Beighton Score ≥5/9  
 
No GJH • 69.3% Anxiety  
• 29.8% Simple phobia 
• 11.9% Agoraphobia 
• 34.2% Panic  
 
Martin-Santos et al 1998 
(113) **  
99 subjects – newly 
diagnosed untreated panic 
disorders and agoraphobia  
99 Psychiatric patients - 
control 
64 Medical clinic patients  
Beighton Score ≥5/9 to 
establish diagnosis of 
“JHS” 
No GJH • 67.7% of patients with newly 
diagnosed anxiety disorders 
had joint hypermobility 
compared to 10.1% in 
psychiatric patients and 12.5% 
in medical patients  
• Patients with anxiety were 16 
times more likely to have joint 
hypermobility compared to 
control subjects 
 
Bulbena et al 2006 (114) 182 “JHS” 
1123 Control subjects 
General adult population  
Beighton score ≥4/9 
men and ≥5/9 for 
women to establish 
“JHS” group  
 
No GJH • Both men and women in joint 
hypermobility group 
significantly higher mean 
scores on the Fear Survey 
Schedule compared to control 
• 43/44 women and 36/39 men 
rated specific fears 
significantly greater intensity 
compared to control group 
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Ercolani et al 2008 (115) 30 “BJHS” subjects 
25 Healthy Control 
30 Fibromyalgia 
Beighton ≥ 5/9  
No musculoskeletal 
symptoms 
No GJH • Significantly higher mean 
scores compared to control for 
7/9 scales on the Illness 
behavior questionnaire 
including; general 
hypochondriasis, disease 
conviction, affective inhibition, 
affective disturbance, denial, 
irritability, and  Whiteley Index 
for Hypochondria 
 
Garcia Campayo et al 
2010 (116) 
55 Untreated patients with 
panic disorers 
55 Fibromyalgia control 
55 Healthy Control 
55 Psychiatric patient 
control 
Beighton ≥ 5/9  
 
No GJH • 61.8% of patients with panic 
disorders had joint 
hypermobility, compared to 
10.9% in psychiatric control 
group.  
• Individuals with joint 
hypermobility within the panic 
disorder group were 
significantly younger (35.2yrs)  
compared to non-hypermobile 
(41.7ys) 
 
Mallorqui-Bague et al 
2015 (117) 
51 non-clinical volunteers.  
 
Beighton score ≥4/9 
men and ≥5/9 for 
women to establish 
“JHS” group  
 
No GJH Participants underwent functional 
MRI evaluation and completed state 
and trait anxiety questionnaire: 
• Joint hyper mobility scores 
associated with anxiety trait 
and brain responses in the 
emotion processing centers of 
the brain when viewing 
emotional faces 
• Suggested hypermobility 
contributes to vulnerability 
anxiety and somatic symptoms 
* Study conducted prior to publication of the criteria for Hypermobility Syndrome (HMS, AKA JHS) in 1992(45), ** Study conducted prior to 
publication of the Revised Brighton Criteria(16)
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Research clearly investigating connective tissue disorders such as EDS has found that 
up to 70% of sufferers seek the care of mental health professionals at some stage 
during their life (118).  The specific diagnosis of JHS/EDS-HT has been associated 
with increased incidence of anxiety, depression, somatosensory amplification (119),  
and general hypochondriasis (115), with individuals being reported to have a 4.3 
times increased lifetime risk of developing any psychiatric disorder compared to the 
general population (120).   
 
Anxiety has been linked to the presence of joint hypermobility with a number of 
papers documenting higher rates of anxiety in individuals with Beighton scores of > 
5/9 when compared to other psychiatric populations and the general community 
(Table 1.11).  However, the reported incidence of symptoms related to anxiety in 
individuals specifically diagnosed with JHS/EDS-HT, is less well defined.  The 
prevalence of anxiety affecting individuals with this explicit diagnosis have ranged 
from 32% (55) to 73% (9, 55).  A study that grouped participants diagnosed with all 
subtypes of EDS demonstrated 74.8% of individuals had levels of anxiety symptoms 
indicative of “probable” clinical diagnosis (121).  Recent findings have reported no 
definite association between panic disorders and the specific diagnosis of JHS/EDS-
HT (120), which is conflict with previous reports linking the presence of joint 
hypermobility, not specifically associated with an HDCT, with panic disorders (Table 
12). Depressive symptoms in the JHS/EDS-HT population have been reported to 
range between 38% (55) to 69% (9, 55), with symptom levels reaching a “probable” 
clinical level in 22.4% of those with a general diagnosis of EDS (121).   Obsessive 
Compulsive Disorders have been reported by 10.6% of individuals with JHS/EDS-HT 
(120).  In addition to axis 1 depressive disorders, JHS/EDS-HT have been associated 
with a 5.8 higher risk of personality disorders compared to unaffected individuals, 
with a reported incidence of 21% (120). 
 
A potential mechanism identified in both GJH and JHS/EDS-HT which may 
contribute to psychological distress is the presence of somatosensory amplification, 
defined as the tendency to perceive somatic sensations as noxious, intense and 
concerning (122).  Somatosensory amplification typically involves a hyper-vigilance 
and focus on unpleasant sensations, misinterpretation of normal visceral and somatic 
sensations as pathological or indicating the presence of disease and the tendency to 
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focus on infrequent sensations (119).  It has been hypothesized that somatic 
amplification may play a role in the increased incidence of anxiety and concern 
regarding somatic symptoms reported by individuals affected by both GJH and 
JHS/EDS-HT (117). 
 
The true incidence and type of psychological manifestations associated in JHS/EDS-
HT are areas that could be confirmed with further specific research in this patient 
population permitting the potential to improve the assessment and management of 
individuals with the condition.  
Functional impairments and physical activity participation: 
Functional impairment related to reduced mobility, participation in work and daily 
activities and physical activity have been reported in JHS/EDS-HT.  Measurement of 
functional impairments in EDS-HT using the Sickness Impact Profile (SIP) have 
identified EDS-HT (N =72) subjects as having comparable overall functional 
impairment compared to fibromyalgia (FM) patients (N=69) and significantly worse 
performance on the SIP compared to those with a diagnosis of rheumatoid arthritis 
(RA) (N= 65) (p < 0.05) (7).  While specific items on the SIP showed EDS-HT was 
associated with significantly greater impairments in the physical and psychosocial 
domains when compared to RA.  The domains of the SIP that were associated with 
the greatest levels of dysfunction in EDS-HT were recreation, hobbies, home 
management, sleep and rest, alertness and work (7).   The specific work related 
impact of JHS/EDS-HT has been documented in a large cross sectional questionnaire 
based study including 466 adults diagnosed with JHS (9).   Of those who were 
currently working (55%), 52% of individuals reported they had changed their working 
role or duties as a result of their symptoms and 82% believed JHS impaired their 
performance at work (9). 
 
There is a lack of research specifically about the impact of JHS/EDS-HT on 
participation in physical activity. Rombaut et al 2010 investigated the physical 
activity, musculoskeletal manifestations and HRQoL in EDS-HT, comparing 32 
gender and age matched health controls with a sample of individuals diagnosed with 
EDS-HT (5).  The study identified that individuals affected by EDS-HT participated 
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in significantly less sports related physical activity (p < 0.023) despite spending a 
comparable period of time performing leisure activities.  Specific associations have 
been demonstrated between objective measures of mobility such as the ambulation 
sub-scores on the SIP and pain severity in an undifferentiated EDS sample (105).  
Functional impairments relating to mobility have been documented in females 
diagnosed with EDS-HT (N=40) when performing the task of sit to stand from a chair 
compared to unaffected controls.  Women with EDS-HT took significantly longer to 
repeat this task compared to the unaffected control sample (p < 0.001) (123).  This 
study also documented significantly reduced lower limb strength and muscle 
endurance affecting the knee extensors and flexor muscle groups (p < 0.001), as well 
as significantly worse physical function in the EDS-HT group (p < 0.001) particularly 
affecting activities involving bending and walking (123). 
Health Related Quality of Life: 
The concept of Health-Related Quality of Life (HRQoL) is a multidimensional 
paradigm, referring to the complex relationship, and interaction between the impacts 
of disease processes/management, and an individual’s physical, social and 
psychological functioning and wellbeing (124, 125).  In a disease process, such as 
JHS/EDS-HT, where there are significant multisystem manifestations of the disorder, 
there is significant potential for the condition to result in reduced overall HRQoL.  
 
Studies specifically investigating the HRQoL experienced by individuals affected by 
EDS have consistently demonstrated lower QoL when compared to healthy samples 
(107, 121).  The domains of HRQoL affected in individuals with JHS/EDS-HT and 
other subtypes of EDS are not limited to physical functioning or pain but extend to 
include mental health, social functioning and energy levels (Table 1.12).   JHS/EDS-
HT specific studies have shown similar levels of disease impact on QOL as in EDS 
generally.  The current research available in JHS/EDS-HT is however limited to 
pediatric populations or studies with small sample sizes, or minimally affected 
individuals.  
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Table 1.12 Health Related Quality of Life: 
Study Sample Characteristics QOL Instrument Results  Comments 
Rombaut et al 
2010 (5)  
32 Subjects with EDS-HT  
32 Healthy controls  
Median age of EDS-HT 
38yrs 
Rand 36-Item 
Health Survey  
 
Found individuals affected by EDS-HT had significantly 
lower HRQoL compared to controls, specifically: 
• Physical functioning 
• Social functioning 
• Limitations due to physical problems 
• Limitations due to emotional problems 
• Mental health 
• Vitality 
• Bodily pain 
• General health perception  
• Physical component summary 
 
Small sample size – difficulty drawing 
causal links.  
 
EDS-HT specific. 
 
 
Voermanns et 
al 2010 (107) 
273 Participants EDS: 
• 162 EDS-HT  
• 45 Classic EDS 
• 11 Vascular EDS 
• 2 Kyphoscoliotic 
EDS 
• 53 Type unknown.  
 
Mean age 40.7yrs 
 
Short Form-36 Social functioning scores on the SF-36 contributed to 
prediction of fatigue severity in EDS sample. 
 
Severely fatigued individuals had significantly lower 
physical functioning scores on the SF-36. 
Limitation in generalizing results to 
JHS/EDS-HT specific populations, as 
only 59% of participants were EDS-HT 
subtype. 
Berglund et al 
2015 (121) 
250 subjects with EDS 
(30% EDS-HT) 
Mean age 46.15yrs  
Short Form-36 Quality of life measures were significantly reduced 
compared to controls in the domains of: 
• Physical functioning  
• Physical role limitation  
• Bodily pain  
• General health  
• Vitality  
• Social Functioning  
• Emotional role limitation  
• Mental health 
Women reported significantly worse mental health 
related quality of life compared to men affected by EDS. 
Limitation in potential the interpretation 
of results for JHS/EDS-HT specific 
populations as only 30% of participants 
were diagnosed with EDS-HT. 
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Albayrak et al 
2015(126) 
115 subjects with BJHS 
(AKA JHS) 
114 Health Control 
Mean age of BJHS 
30.17yrs and 31.81yrs for  
control group 
Short Form-36 BJHS participants had significantly impaired QoL 
compared to healthy controls in the following domains: 
• Physical functioning  
• Physical role limitation  
• Bodily pain  
• General health  
• Emotional role limitation  
• Mental health 
• Mental Component summary 
Pain scores on SF-36 positively correlated with 
Pittsburgh sleep quality index (PSQI), Beck Depression 
Inventory (BDI) and total Checklist Individual Strength 
(CIS). 
Inverse correlation: 
• between PSQI and physical and mental components 
summaries, the physical role and emotional role 
scores of the SF-36. 
• between BDI and the mental and physical 
component summaries, physical function, role 
physical, role emotional and mental health scores of 
SF-36 
• between CIS score and  physical function, role 
physical , role emotional, physical and mental 
component summaries scores of the SF-36. 
BJHS/JHS specific research. 
Significant limitation in research - 
excluded individuals with  
 
• Pain > 8/10 VAS  
• Using analgesia for pain relief 
•  Anti-depressants, 
• Joint pain related to  
sprains/dislocations/ fractures 
limiting the sample population to the 
minimally affected physically by the 
disorder. 
 
Pacey et al 2015 
(86) 
89 children with JHS  
Mean age 11.5yrs 
Pediatric Quality of 
Life 4.0 Generic 
core scale  
Pediatric QL 
Multidimensional 
Fatigue Scale 
(MFS) 
Multiple regression analysis to determine predictors of 
Child-reported HRQoL 74% of variance in score 
accounted for by: 
• General fatigue  
• Sleep/rest fatigue 
• Pain scores 
• Stress incontinence symptoms 
 
Pediatric population of JSH – limits the 
ability to generalize results to adult 
population.  
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Manifestations of JHS/EDS-HT such as pain, fatigue severity (8), gastrointestinal 
symptoms (99), orthostatic intolerance (81) and genitourinary manifestations (85) 
have been correlated with quality of life measures, with increasing severity of 
manifestation expression associated with worsening HRQoL.   
 
Given the potential impact of the disorder on HRQoL, further larger studies 
specifically investigating the overall impact of JHS/EDS-HT on HRQoL and 
determination of which specific disease manifestations are predictive of HRQoL may 
allow better assessment and more targeted management of individuals potentially 
reducing the impact of the disorder. 
Progressive disability models of JHS/EDS-HT evolution: 
In an attempt to explain the clinical heterogeneity seen in JHS/EDS-HT, particularly 
when comparing the type and severity of symptoms, overall burden of disease and 
HRQoL reported by individuals affected by JHS/EDS-HT, a model has been proposed 
to better define disease progression in the disorder (6, 59, 64). Grahame (2013) 
described three distinct phases of disease progression in JHS/EDS-HT.  The first 
phase of the disability model is proposed to directly relate to manifestations caused by 
laxity of the connective tissue, including joint sprains, articular instability episodes, 
hernias (POP and abdominal hernias) and vascular manifestations such as varicose 
veins.  Phase two is defined by manifestations not specifically related to connective 
tissue laxity such as amplification of pain, the development of fatigue, deconditioning 
related to reduced physical activity and kinesiophobia and manifestations associated 
with autonomic nervous system dysfunction such as gastrointestinal symptoms and 
POTS.  The subsequent expression of psychosocial features such as depression, 
anxiety, decreased function and HRQoL is indicative of the final phase of JHS/EDS-
HT (6).  A similar expanded model was developed by Castori et al (2013) with the 
inclusion sensorimotor manifestations and headaches and  the expansion of  
descriptions relating to fatigue, muscle and visceral manifestations of the JHS/EDS-
HT (64) (Figure 1.7).  
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 Figure 1.7 Model of disease progression in JHS/EDS-HT(64) 
 
The expanded model lacked the emphasis of the significant psychosocial 
manifestations of the disorder as being present during the third phase of disease 
progression.   In attempts to target treatment to a particular phase in disease 
progression, the development of preventative measures based on disease phase was 
developed (Figure 1.8).  The authors acknowledge the need for future prospective 
studies to ascertain the effectiveness of such a model of intervention in JHS/EDS-HT 
(64). 
 
Figure 1.8 Stratification of preventative strategies in JHS/EDS-HT(64)   
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Current management strategies in JHS/EDS-HT 
Despite the recognition of the burden of disease associated with the MSK and 
systemic manifestations of JHS/EDS-HT there are limited management strategies that 
have been tried and tested using randomized control studies.   A large proportion of 
published reports relating to management strategies are case presentations or trials 
involving small sample sizes without control comparison groups.  The range of 
interventional strategies documented in literature relating to the management of 
JHS/EDS-HT include including splinting/bracing, manual therapy, exercise (both 
specific and general), cognitive behavioural therapy (CBT), pain management 
programs, education and proprioceptive exercise programs.  The majority of 
interventions documented are aimed at managing the musculoskeletal manifestations 
of the disorder such as pain, joint stability and muscle strength with little specific 
attention on the systemic features of the condition.  
 
In pediatric samples there has been evidence to suggest supervised exercise programs 
have the ability to decrease pain (127, 128) and improve psychosocial functioning of 
children participating in the interventions (128).  A randomized control trial (JHS, 
N=57, age 7-16yrs) which compared specific targeted exercise program to a general 
exercise program treatment group showed that both groups experienced significant 
reduction in pain levels (p< 0.001) but no differences were found between the groups 
indicating either method of exercise were effective in reducing pain in their cohort of 
subjects (127).  While a RCT investigating physiotherapy lead exercise program, 
comparing supervised knee exercises, being performed either to neutral or 
hypermobile ranges, (N = 26, mean age 12.04yrs, diagnosis of JHS) demonstrated 
significant benefit in terms of psychosocial health, max and mean knee pain scores 
across both groups with no significant child reported differences between groups 
(128). 
 
Improvements in psychosocial wellbeing, HRQoL, specific muscle strength, 
decreased pain and improved proprioception, have been associated with lower limb 
based exercise programs in the adult population of JHS/EDS-HT (Table 1.13).  
Despite consistent recommendations in JHS/EDS-HT literature there are limited 
studies that have investigated the impact of a multidisciplinary approach to the 
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management of the condition accounting for the myriad of multi-system 
manifestations.  Promising findings have been documented in small trials 
investigating the efficacy of MDT management of JHS/EDS-HT with significant 
improvements documented in functional capacity, kinesiophobia, coping mechanisms 
and functional capacity.  However larger randomised control studies are required to 
investigate the efficacy of combined interventions such as graded exercises programs, 
CBT strategies to address kinesiophobia, psychological manifestations and coping 
strategies and pain management strategies, in the management of JHS/EDS-HT. 
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Table 1.13 Management strategies in Adult JHS/EDS-HT (studies with > 10 participants) 
Study Sample 
characteristics 
Intervention Results Comments 
Ferrell et al 2004 
(129) 
20 patients 
diagnosis of JHS 
based on revised 
Brighton  (18 
completed study) 
 
Mean age 27.3 
Home based physiotherapy lower limb 
exercise program: - Closed connectic chain exercises  - Hamstring exercises  
8 week program – exercise 4/7days per 
week.  
 
10 patients were measured at commencement and 
repeated 2-8 weeks later.  
 
Significant changes in: - Significant improvement in QoL measured 
with SF-26 in physical functioning (p= 0.029) 
and mental health (p= 0.008) summary scores  - Decreased pain (p = 0.003) - Increased muscle strength hamstring and 
quadriceps - Improved proprioception (p < 0.001) 
 
Small sample size.  
 
Measurements not 
taken at a 
standardized interval.  
 
Loss of 8 patients at 
reassessment. 
 
Sahin et al 2008 (130) 40 individuals with 
a diagnosis of BJHS  
 
Randomised control 
trial  
 
Exercise group 
15participants 
Mean age 25.6yrs 
 
Control 25 
participant  
Mean age 27.68yrs 
Proprioceptive exercise program for 8 weeks 
in exercises group.  
 
 
- Exercise group reported a significant reduction 
in both activity an resting VAS (Pain) (p<0.05) - No Significant change in VAS (rest or with 
activity) in control group (p >0.05) - Occupational activity component of the 
Arthritis Impact Measurement Scale – 2  
showed significant improvement in the 
exercise group (p <0.05) - Proprioception acuity in the knees was 
improved in the exercise group only (p < 
0.001)  
 
Randomised control 
study.  
 
Small sample sizes.  
 
Intervention limited to 
proprioceptive 
exercises in exercise 
group.  
Bathen et al 2013 
(131) 
12 women 
diagnosed with 
JHS/EDS-HT 
 
Mean age 35 
 
Multidisciplinary management of JHS/EDS-
HT involving cognitive behavioural therapy 
(CBT), education and structured exercises 
program.  
 
Two and a half week inpatient program, 
followed by individual home exercise 
program (3 months) and 4 days of inpatient 
retesting and advice.  
Significant improvements were found: - Canadian Occupational Performance Measure 
both performance (p = 0.008) and satisfaction 
(P = 0.005) measures - Tandem backwards walking (p = 0.006)  - Stair walking up (p = 0.004) (down not 
significant (p = 0.065)) - Calf raises  - Kinesiophobia measures (0.022) 
No control 
comparison group.  
Small sample size.  
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Multidisciplinary team: - Physiotherapist - Doctor  - Registered Nurse - Social work  - Occupational therapy  
 
Pain rating did not show improvements.  
 
Rahman, Daniel and 
Grahame 2014 (132) 
87 Participants – 
JHS with pain for 
greater than 3 
months 
 
Mean age 35 years  
Pain management program (CBT)over 6 
weeks  (8 days). 
 
Multidisciplinary team approach: - Physiotherapist - Rheumatologist - Nurse  - Psychology  
 
Significant improvements in measures at 1 month 
post program: - Self efficacy  - Pain catastrophising  - Depression  - Anxiety  - Frustration  - Impact on daily life  - Average pain intensity 
 
5 months post program – results were remained 
improved compared to baseline except for pain 
intensity.  
No control 
comparison for study.  
Drop out of 25% at 5 
month follow-up.  
 
Pain levels showed 
the smallest 
improvements.  
 
Pain catastrophising, 
self efficacy, 
frustration and impact 
on daily life showed 
greatest improvement 
at one month follow-
up, > 20% 
improvement 
compared to baseline 
measures.  
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Conclusion: 
The complexity and multisystem clinical presentation of JHS/EDS-HT has been 
exposed significantly over the last 3 decades.  Features that have been identified as 
having significant impact on HRQoL in JHS/EDS-HT include pain, including acute 
and chronic widespread pain, significant fatigue, gastrointestinal symptoms, 
orthostatic intolerance and cardiovascular manifestations.  There is however an 
ongoing need to investigate and progress the understanding of the JHS/EDS-HT to 
help define the full extent, mechanisms and impact of the non-musculoskeletal 
manifestations of the disorder.  In particular, there is a need to better understand the 
mechanisms contributing to the expression of significant fatigue, psychological, 
autonomic and gastrointestinal manifestations of the disorder and overall HRQoL.  
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Chapter Two  
Aims and Objectives of the Thesis 
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Aims of thesis: 
The primary aims of this thesis are to improve the knowledge relating to the systemic 
manifestations of JHS/EDS-HT, particularly relating to fatigue severity, 
psychological wellbeing and overall HRQoL, to help direct improvements in the 
diagnostic process and development of targeted management strategies for individuals 
affected by JHS/EDS-HT. 
 
Objectives of the thesis: 
To achieve the aims of this thesis the following objectives were set: - Define the symptom profile of an adult sample of individuals with JHS/EDS-
HT  - Investigate the prevalence and significance of non-musculoskeletal/systemic 
features of the disorder: 
o Fatigue  
o Psychological manifestations of JHS/EDS-HT 
o Gastrointestinal and cardiovascular  - Determine satisfaction levels associated with current diagnostic and 
management strategies in JHS/EDS-HT. - Define the levels of activity participation in JHS/EDS-HT  - Quantify the HRQoL experienced by individuals with JHS/EDS-HT - Identify potential determinants of: 
o Fatigue severity  
o HRQoL 
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Chapter Three  
Fatigue Severity in Joint Hypermobility 
Sydrome/Ehlers-Danlos Syndndrome – 
Hypermobility Type 
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Study 1: Features that exacerbate fatigue severity in Joint Hypermobility 
Syndrome/Ehlers-Danlos Syndrome – Hypermobility Type.  
 
This study has been published in the journal Disability and Rehabilitation: 
Krahe AM, Adams RD, & Nicholson LL (2017). Features that exacerbate fatigue severity in Joint Hypermobility 
Syndrome/Ehlers-Danlos Syndrome – Hypermobility Type. Disability and Rehabilitation (submitted 25 October 2016). 
 
Co-authors’ Statement 
As co-authors of the paper Features that exacerbate fatigue severity in Joint Hypermobility Syndrome/Ehlers-Danlos 
Syndrome – Hypermobility Type 
we confirm that Anne Krahe has made the following contributions: 
• Conception and design of the research 
• Collection and extraction of data 
• Analysis and interpretation of the findings 
• Drafting and revising of the paper and critical appraisal of the content 
 
 
 
Leslie Nicholson 
Date 3/8/2017 
 
 
 
Roger Adams  
Date 3/8/2017 
 56 
DISABILITY AND REHABILITATION, 2017 https://doi.org/10.1080/09638288.2017.1323022 ORIGINAL ARTICLE Features that exacerbate fatigue severity in joint hypermobility syndrome/ Ehlers–Danlos syndrome – hypermobility type Anne Maree Krahea, Roger David Adamsb and Leslie Lorenda Nicholsona 
aDiscipline of Biomedical Science, School of Medical Sciences, Sydney Medical School, The University of Sydney, Sydney, Australia; bDiscipline of 
Physiotherapy, Faculty of Health Sciences, The University of Sydney, Sydney, Australia 
ARTICLE HISTORY Received 25 October 2016 Revised 11 April 2017 Accepted 21 April 2017 
KEYWORDS Health-related quality of life; hypermobile Ehlers–Danlos syndrome; hypermobility syndrome; mental health; physical activity; orthostatic intolerance 
Introduction 
Joint hypermobility syndrome (JHS) and Ehlers–Danlos syndrome – 
hypermobility subtype (EDS-HT) are chronic heritable connective tis- 
sue disorders that are characterized by generalized joint hypermo- 
bility and a combination of musculoskeletal and multisystem 
symptoms and signs. The diagnosis of JHS/EDS-HT is made on the 
phenotypical presentation, together with medical and family history 
as no genetic markers have as yet been identified [1,2]. There is 
growing consensus that despite being diagnosed with different cri- 
teria (Table 1), JHS (Brighton criteria) [3] and EDS-HT (Villefranche 
criteria) [4] are indistinguishable conditions and consequently the 
same phenotypic disorder [1,2,5,6]. The multi-system features of 
this condition include polyarthralgia, joint instability, skin fragility 
and hyperextensibility, gastrointestinal and autonomic dysfunction 
[7] and fatigue [8–11]. 
Research focusing on the non-musculoskeletal features across 
all subtypes of EDS has identified fatigue as one of the most 
debilitating symptoms reported by individuals affected by the dis- 
orders [12–14]. Fatigue is widely acknowledged as a disabling 
symptom affecting health-related quality of life and psychological 
well-being  in  a  range  of  chronic  health  conditions    [15–20]. 
The prevalence of severe fatigue in JHS/EDS-HT has been reported 
to range from 84% [13] to 88% [21]. To date, research into fatigue 
severity has predominantly focused on the combined subtypes  
of EDS, with little research solely investigating the more common 
subtype of this condition, EDS-HT. 
To further evaluate the symptoms and signs of JHS/EDS-HT 
and better understand the impact of fatigue on individuals with 
this condition, this study set out to determine the signs and 
symptoms of JHS/EDS-HT associated with fatigue severity and to 
identify which features predict an individual’s fatigue level. As 
fatigue has the potential to significantly affect the quality of life in 
individuals with this condition, is particularly important to deter- 
mine whether modifiable factors associated with fatigue severity 
can be identified. 
Materials  and methods 
Participants 
Adult participants (16–65 years of age) were recruited via adver- 
tising on EDS websites (ConnecTed and EDSAUS) and word of 
mouth. Respondents who had a diagnosis of JHS or EDS-HT 
CONTACT Anne Krahe akra2983@uni.sydney.edu.au Discipline of Biomedical Science, The University of Sydney, PO Box 170, Lidcombe, NSW 1825, Australia © 2017 Informa UK Limited, trading as Taylor & Francis Group 
 ABSTRACT 
Aim: To assess the prevalence, severity and impact of fatigue on individuals with joint hypermobility syn- 
drome (JHS)/Ehlers–Danlos syndrome – hypermobility type (EDS-HT) and establish potential determinants 
of fatigue severity in this population. 
Methods: Questionnaires on symptoms and signs related to fatigue, quality of life, mental health, physical 
activity participation and sleep quality were completed by people with JHS/EDS-HT recruited through two 
social media sites. Multiple regression analysis was performed to identify predictors of fatigue in this 
population. 
Results: Significant fatigue was reported by 79.5% of the 117 participants. Multiple regression analysis 
identified five predictors of fatigue severity, four being potentially modifiable, accounting for 52.3% of the 
variance in reported fatigue scores. Predictors of fatigue severity were: the self-perceived extent of joint 
hypermobility, orthostatic dizziness related to heat and exercise, levels of participation in personal rela- 
tionships and community, current levels of physical activity and dissatisfaction with the diagnostic process 
and management options provided for their condition. 
Conclusion: Fatigue is a significant symptom associated with JHS/EDS-HT. Assessment of individuals with 
this condition should include measures of fatigue severity to enable targeted management of potentially 
modifiable factors associated with fatigue severity.       IMPLICATIONS  FOR REHABILITATION 
• Fatigue is a significant symptom reported by individuals affected by joint hypermobility syndrome/ Ehlers–Danlos syndrome – hypermobility type. 
• Potentially modifiable features that contribute to fatigue severity in this population have been identified. 
• Targeted management of these features may decrease the severity and impact of fatigue in joint hypermobility syndrome/Ehlers–Danlos syndrome – hypermobility   type. 
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2 A. M. KRAHE ET AL. 
Villefranche Criteria for EDS-HT [4] JHS – Brighton Criteria [3] Major Criteria Major Criteria 1. Beighton ≥ 5/9 1. Beighton  ≥4/9 2. Skin involvement (hyperextensibility and/or smooth, velvety skin) 2. Arthralgia for >3 months in ≥ four joints Minor Criteria Minor  1. Recurring joint dislocations 
2. Chronic joint or limb pain 
3. Positive family history 1. Beighton score 1–3/9 if >50 years old 2. Arthralgia >3 months in 1–3 joints or back pain >3 months 3. Dislocation/subluxation in >1 joint or in one joint on more than one occasion 4. Soft tissue rheumatism >  three lesions 
5. Marfanoid habitus 
6. Abnormal skin: striae, hyperextensibility, thin skin, papyraceous scarring 
7. Eye signs: drooping eyelids or myopia or antimongoloid slant 
8. Varicose veins or a hernia or rectal or uterine prolapse JHS is diagnosed in presence of 
1. Two major criteria 
2. One major and two minor criteria 
3. Four minor criteria 
4. Two minor criteria where there is an unequivocally affected first-degree relative JHS is excluded in the presence of Marfan syndrome or EDS (other than EDS-HT). 
The presence of one or more major criteria is either necessary for clinical diagnosis or highly indicative and warrants laboratory confirmation whenever possible. Minor criteria points differentiate between subtypes of EDS but are not sufficient in the absence of major criteria findings for a diagnosis of EDS-HT. EDS-HT: Ehlers–Danlos syndrome – hypermobility type; JHS: joint hypermobility syndrome. 
were included in this study. Those respondents who had a 
preexisting diagnosis of Marfan syndrome, Osteogenesis 
Imperfecta, EDS Type I, II or IV, Stickler’s disease or Loeys–Dietz 
syndrome were excluded from the study. Once consent was 
gained, a questionnaire was administered and those able to 
attend in person participated in a physical examination. Ethical 
approval to conduct this research was granted by The University 
of Sydney’s Human Research Ethics Committee (Protocol number 
2012/558). 
hearing/taste). Internal consistency of the four domains is rated as 
acceptable to good in a community, non-diseased sample 
(Cronbach’s a range: 0.73–0.86), while relationships and senses are 
rated as questionable to poor respectively [24]. The tool is 
described as possessing appropriate levels of construct, concur- 
rent and divergent validity [24]. Each dimension is scored between 
0.0 and 1.0, with higher scores indicating the better perceived 
health-related quality of life [25]. 
Mental health 
The psychological well-being of each participant was measured 
using the Depression Anxiety Stress Scale (DASS-21), a 21-item, 
self-report measure consisting of three dimensions; depression, 
anxiety and stress. The DASS-21 has acceptable to excellent 
internal consistency and normative data have been reported 
[26,27]. The DASS-21 individual scores were doubled to enable an 
interpretation of the severity of the individual dimension scores 
using DASS-42 data [28], a method shown to produce a valid 
interpretation of the DASS-21 values [26]. A higher score indicates 
poorer mental health. 
Questionnaires 
Demographic data and information relating to the symptoms and 
signs associated with connective tissue disorders were 
obtained. Information regarding previous surgery, use of analge- 
sics and co-morbidities was recorded and structured question- 
naires were used to ascertain the self-perceived fatigue, health- 
related quality of life, mental health, joint hypermobility and 
activity participation. 
Fatigue 
The Fatigue Severity Scale (FSS) [17], a nine-item self-report scale 
with a range 9–63, measured fatigue using both total and mean 
of individual scores. Higher scores represent greater perceived 
fatigue. The FSS has previously been utilized to investigate fatigue 
in JHS/EDS-HT [21], chronic health conditions where fatigue is a 
significant symptom, including chronic fatigue syndrome, fibro- 
myalgia [16], systemic lupus erythematosus [17], multiple sclerosis 
[17,22] and Marfan syndrome [23]. Normative FSS values are avail- 
able for healthy adult populations [17,22]. The FSS has been 
shown to have excellent internal consistency and high test–retest 
reliability [22]. A mean fatigue severity individual score of 4 out of 
a possible 7 [22] or a total score of 36/63 [17] are the cutoffs indi- 
cating significant fatigue. 
Physical activity 
The Physical Activity Index is a composite score, with three indi- 
vidual components; intensity (1–5), duration (1–4) and frequency 
(1–5).   The   composite   score   is   calculated   as   Intensity x 
Duration x Frequency ¼ total score/100. The total score is used to 
classify an individual’s current physical activity participation as 
sedentary (<20), poor (20–39), fair (40–59), very good (60–80) or 
high (81–100) [29]. 
Historical generalized joint hypermobility  measure 
The Hakim 5 [30] is a five-item self-report questionnaire for identi- 
fying hypermobility that requires yes/no responses. Two of the 
questions relate to hypermobility at specific joints while the 
remaining three require the participant to attend to historical and 
general aspects of joint flexibility. The questionnaire is reported to 
have 83% sensitivity and 89% specificity for diagnosing general- 
ized hypermobility [30]. A positive response to two or more of the 
five questions results in an accurate diagnosis of generalized joint 
hypermobility 84% of the time. 
Quality of life 
The Assessment of Quality of Life (AQoL)-6D, a multidimensional 
20-item instrument measuring self-reported, health-related quality 
of life was utilized. The instrument assesses six dimensions of 
health-related quality of life; independent living, mental health, 
coping,  relationships,  pain  and  senses  (i.e., sight/smell/touch/ 
 
 
 
 Table 3.1 Diagnostic Criteria for EDS-HT (Villefranche Criteria) and JHS (Brighton Criteria) 
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Physical examination measures 
Those able to attend  underwent  a  physical  examination,  
which included assessment of hypermobility using the Beighton 
score [31]. 
Table 3.2 Specific diagnosis provided by medical professionals related to partic- ipant’s  joint hypermobility. Diagnosis related to joint hypermobility symptoms/signs Frequency % Diagnosis relating to joint hypermobility EDS/HT JHS Diagnosed with both JHS and EDS-HT Comorbid diagnosis Fibromyalgia (comorbid) Chronic fatigue syndrome (comorbid) Generalized joint hypermobility (comorbid) 
65% (n = 76) 27% (n = 32) 8% (n =  9) Statistical analysis 
SPSS (version 23, Chicago, IL) was utilized for data analysis. 
Descriptive statistics were used to define the study sample. 
Correlation analysis was performed using Pearson’s coefficient (r), 
with the level of significance set at a probability (p) value of less 
than 0.05. Stepwise multiple regression analysis was performed, 
with fatigue (FSS individual mean score) as the dependent vari- 
able, and eight variables representing dimensions of JHS/EDS-HT 
entered as independent variables. The variables identified in the 
final model of the multiple regression analysis were viewed as 
predictors of fatigue severity in this group. 
11% (n =  13) 7% (n =  8) 7% (n =  8) Osteoarthritis  3% (n = 3) Satisfied with diagnosis and management 42% (n = 49) EDS-HT: Ehlers–Danlos syndrome – hypermobility type; JHS: joint hypermobility syndrome. Table 3.3 The extent of hypermobility and connective tissue related measures in the group. Connective  tissue features Mean (SD) Beighton (out of 9) Hakim 5 (out of 5) Number of painful joints Number of painful muscles Number of fractures Number of dislocations Number of connective tissue-related surgeries Ease of bruising (100 mm VAS)a Urinary incontinence (100 mm VAS scale)b 
5.8 (1.8) 3.8 (1.1) 9.4 (5.3) 3.1 (3.3) 1.9 (3.5) 2.2 (3.3) 1.5 (2.9) 65.1 (25.2) 37.8 (34.7) 
Results 
Participant background 
Data were available for 117 participants (110 female and 7 male), 
with a mean age (SD) of 35.0 years (12.1). Fifty-nine participated 
in both the physical examination and questionnaire component of 
the study. Participants were asked to record any diagnosis they 
had received from medical professionals relating to their joint 
hypermobility (Table 2). 
a0: hardly at all; 100: extremely easily. b0: never leaking urine on cough/jump; 100: often. VAS: visual analog scale. 
Connective tissue features of JHS/EDS-HT 
Table 3 provides the mean (SD) results of hypermobility tests as 
continuous measures and physical self-report data. Of the subjects 
Table 3 . 4 Correlation (Pearson’s r) between mean fatigue score and hypermobility, joint and muscle pain, physical activity,  sleep  duration,  mental  health, QoL, dysautonomia and symptoms of urinary incontinence. 
who completed the questionnaire, 96.5% met the ?_2/5 cutoff for   Correlation with fatigue 0.314** identification of generalized joint hypermobility using Hakim     5, Hakim 5 total score Number of joints affected by pain Number of muscles affected by pain Physical activity index total composite score Average hours/night sleep DASS-21 Depression DASS-21 Anxiety DASS-21 Stress AQoL relationship dimension AQoL coping dimension AQoL pain dimension AQoL total score Dizziness VAS Incontinence VAS Stool frequency 
0.346** while 88.1% met the ≥4/9 Beighton cutoff. 0.279** Self-report information on musculoskeletal related features of -0.438** 
JHS/EDS-HT was collected. Of those who had a history of fractures, 
43.8% reported they had suffered a fracture as a result of low force 
trauma. Joint dislocations occurred during childhood in 48.3% of 
individuals. Hernias were present in 24.8% of participants. 
0.047 0.286** 0.385** 0.158 ** -0.615** -0.570** -0.526** Fatigue 
The cutoff for severe fatigue was met by 79.5% of the cohort. A 
mean (SD) total fatigue severity score of 48.8/63 (14.5) and indi- 
vidual fatigue score of 5.4/7 (1.6) were recorded. Figure 1 demon- 
strates the mean severity of reported fatigue of JHS/EDS-HT 
participants in this study compared to those in studies of other 
chronic diseases. Fatigue significantly correlated with a range of 
musculoskeletal, non-musculoskeletal, health-related quality of life 
and mental health measures (Table 4). The mean (SD) duration of 
sleep per night was 6.9 h (2.0). Participants answered questions in 
relation to the quality of their sleep with the following responses; 
90% reported not feeling refreshed on waking, 70% were awoken 
by discomfort, 37% reported snoring, 69% reported difficulty get- 
ting to sleep with 66% of this reporting requiring longer than     
20 min to fall to sleep on a typical night. 
0.712 - ** 0.350 0.191* 0.146 DASS: depression anxiety stress scales; AQoL: assessment of quality of life instru- ment; VAS: visual analog scale. *indicates p ::: 0.05, **indicates p ::: 0.005. 
been medically diagnosed in 21.6%, with the specific diagnosis of 
postural orthostatic tachycardia syndrome in 16.4% and ortho- 
static intolerance in 5.2%. Dizziness was measured on a visual ana- 
log  scale  (VAS)  (0 = “never”  and  100 =  “often”  experiencing 
dizziness), the mean score (SD) was 73.8 (28.9). 
Gastrointestinal complaints that could be attributed to the 
autonomic nervous system were present in 26.7% of participants. 
The frequency of passing stools was measured on a scale of 1–6, 
where 1 represented passing stool more often than once per day 
and 6 represented less than once per week. The mean (SD) was 
2.3 (1.2) representing passing stools “once a day”. The medical 
diagnosis of gastroparesis was reported by 1.7% and irritable 
bowel syndrome by 15.5% of the sample. 
JHS/EDS-HT related autonomic nervous system dysfunction 
Autonomic nervous system dysfunction, relating to the cardiovas- 
cular and  gastrointestinal  systems,  was  reported  by  42.2%  
of participants. Cardiovascular-related autonomic dysfunction had 
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Figure 3.1. Mean individual fatigue score for JHS/EDS-HT in the current study, n = 117 (diagonally hatched bar) compared to healthy adults and people with other chronic diseases. The dashed horizontal line represents the criterion for severe fatigue of > 4/7. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) (n =  123) [16]; multiple sclerosis (MS) (n =  25), systemic lupus erythematosus (SLE) (n = 29) and healthy adults (n =  20) [17]; JHS/EDS-HT (n =  42) [21]; multiple sclerosis (MS) (n = 188) [22]; Marfan syndrome (n = 73) [23]. FFS: fatigue severity score; EDS-HT: Ehlers–Danlos syndrome – hypermobility type; JHS: joint hypermobility syndrome. 
Quality of life and mental health 
The mean (SD) total AQoL score was 0.61/1 (0.14) and the 
individual component scores were: independent living 0.64  
(0.22), relationships 0.68 (0.19), mental health 0.59 (0.15),  cop- 
ing 0.50 (0.17), pain 0.41 (0.22) and senses 0.81 (0.11).   Figure 
2 compares these total and composite scores with normative 
data. 
The DASS-21 was utilized to evaluate the dimensions of an 
individual’s mental health. The individual dimension scores of 
depression, anxiety and stress were doubled as were the total 
DASS-21 scores [26], so that they could be compared with norma- 
tive data using the DASS-42. The mean (SD) depression score was 
10/42 (8.7), anxiety 9.35/42 (7.2), stress 15.7/42 (9.1) with the com- 
bined total score 35.0/126. These mean scores, normative values 
for a healthy adult population [26] and mean scores for a chronic 
pain cohort are presented in Figure 3. 
Multiple regression analysis 
A stepwise multiple regression analysis was conducted with the 
Mean Fatigue Severity Score as the dependent variable and 
eight independent variables entered; Hakim 5 (self-perceived 
joint hypermobility), DASS-21 depression total score (mental 
health), dizziness VAS (cardiovascular/orthostatic autonomic 
symptoms), frequency of stool motions (gastrointestinal related 
symptoms), pain dimension of the AQoL, relationship dimension 
of the AQoL (related to participation in community/family), per- 
ceived satisfaction with diagnosis and treatment options pro- 
vided by treating practitioners (dichotomous choice where “0” 
represents dissatisfied and “1” represents satisfaction) and 
Physical Activity Index composite score (physical activity partici- 
pation).  Using  the  method  of  simple  regression  imputation to 
account for missing data (DASS-21 Depression N =0, AQoL rela- 
tionship dimension N =11 and AQoL pain dimension N = 11) 3% 
of the total data were replaced [32]. The regression analysis pro- 
duced a model that accounted for 52.3% of the variance in the 
FSS mean individual score, with five predictors of fatigue sever- 
ity. The resulting regression equation for predicting an individu- 
al’s mean FSS was: 
Physical activity 
Mean physical activity participation resulted in a mean Physical 
Activity Index score of 25.5/100, which placed the cohort in the 
“poor” category with respect to their current activity levels. Of the 
cohort, 50% were sedentary, 28% poor, 10% fair and only 12% 
very good or highly active. 
Mean Fatigue Severity Score = 6.5–3.7 (AQoL   Relationship 
Dimension score) + 0.012 (Dizziness VAS) – 0.017 (Physical Activity 
Index Total Score) – 0.54 (Patient Satisfaction) + 0.32     (Hakim 
5 Score). 
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From the examination of possible determinants of fatigue severity 
in individuals who met the diagnostic criteria for JHS/EDS-HT, five 
predictors of fatigue severity were identified: the self- 
perceived extent of joint hypermobility, orthostatic dizziness, 
participation in personal relationships and community, physical 
activity and satisfaction with medical management and treatment 
options offered by health professionals. This set of predictor varia- 
bles for fatigue severity represents features that collectively chal- 
lenge an individual’s capacity to cope with their condition. 
Although the measure of historical joint hypermobility (the Hakim 
5 score) is not modifiable, the identification of potentially modifi- 
able predictors of fatigue gives researchers and clinicians the pro- 
spect of developing and improving treatment and referral 
pathways for the management of fatigue in this clinical population. 
This study corroborates findings of previous research identify- 
ing fatigue as a significant clinical symptom for people with JHS/ 
EDS-HT. The prevalence of severe fatigue in this sample of the 
JHS/EDS-HT was 79.5% when measured using the FSS, a figure 
comparable to previous reports of prevalence in this population 
ranging from 84% [13] to 88% [21]. The proportion of the current 
sample who reported significant fatigue was not significantly 
lower compared to the cited studies (both p > 0.22). Previous 
research, which has investigated fatigue severity in the setting of 
EDS, has taken a general approach to the condition by including 
all five subtypes of EDS in the cohort sample. Multiple regression 
analyses performed in these studies were able to account for 38% 
[13] and 27% [12] of the variance in the FSS, values less than the 
current sample where 52.3% of the variance in the FSS was 
accounted for by five variables. The relatively homogenous sample 
in the current study, including only JHS/EDS-HT subjects, may 
explain the improved ability to identify features that account for 
fatigue severity. 
In terms of outcomes, there are similarities between the current 
study and those previously undertaken, with pain severity identi- 
fied as significantly associated with fatigue severity [12,13]. The 
current study did not, however, identify pain severity as a predictor 
of fatigue in this population. Disease-related features, such as 
higher self-perceived hypermobility and reduced social function- 
ing, ranging from participation in the family to community-based 
activities, were predictive of higher levels of fatigue in the current 
study and that of Voermans et al. (2010) [13]. Further research on 
the construct validity of the AQoL-6D in chronic pain cohorts is 
required to determine the internal consistency of the tool. 
The current study has identified three further predictors of 
fatigue severity in addition to those previously described. Results 
indicate that physical activity participation, orthostatic dizziness 
associated with heat and exercise, and satisfaction with the diag- 
nosis and management offered by health professionals, also 
Figure 3.2 Mean AQoL total score and means of the six component scores for JHS/EDS-HT participants in the current study, n = 106 (diagonally hatched bars) com- pared to normative scores. [25] Normative values for AQoL-6D (n= 2731). AQoL-6D: assessment of quality of life – 6 dimensions; EDS-HT: Ehlers–Danlos syndrome – hypermobility type; JHS: joint hypermobility syndrome. 
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Figure 3.3 Mean DASS 21 dimensional scores for JHS/EDS-HT participants, n = 107 (diagonally hatched bars), with comparative data; each dimension score range is 0–42. The dashed horizontal lines represent the cutoff scores for mild symptom severity for depression (10), anxiety (8) and stress (15) [28]. [15] Chronic pain popula- tion DASS Depression dimension (n = 2445) and DASS anxiety dimension (n = 2421); [26] normative data for DASS-21 (n = 1794). DASS-21: Depression Anxiety Stress Scales, 21 item version; EDS-HT: Ehlers–Danlos syndrome – hypermobility type; JHS: joint hypermobility syndrome; norm: normative. 
contribute to the prediction of fatigue severity in JHS/EDS-HT 
participants. 
While Voermans et al. (2011) found no association between 
activity participation and fatigue severity, in the current cohort 
physical activity participation was a determinant of FSS scores, 
with lower activity participation, measured using the composite 
Physical Activity Index score, associated with higher levels of 
fatigue. This discrepancy may be due to the heterogeneity of the 
sample in Voermans et al.’s study, where only 17% of their EDS 
participants had EDS-HT [12]. 
Orthostatic intolerance is a condition related to autonomic 
nervous system dysfunction and symptoms include dizziness, 
palpitations and syncope. Episodes  are  typically  precipitated 
by orthostatic changes and can be exacerbated by physical exer- 
tion and heat [33]. Orthostatic intolerance is a significant non- 
musculoskeletal complaint which has been associated with JHS/ 
EDS-HT and prevalence of symptoms has been reported as up to 
78% of individuals with a diagnosis of JHS [34]. Fatigue has previ- 
ously been linked to postural orthostatic tachycardia syndrome, a 
form of orthostatic intolerance [35], with 58% of individuals with 
JHS-related postural orthostatic tachycardia syndrome suffering 
from clinically significant fatigue [36]. The findings of the current 
research showed that 22% of participants reported symptoms 
related to orthostatic intolerance and its contribution to fatigue 
severity in the multiple regression supports previous research link- 
ing orthostatic intolerance to fatigue [36]. A higher frequency of 
dizziness related to heat, exercise and or postural change was sig- 
nificantly correlated with and a predictor of, fatigue severity. 
Orthostatic intolerance is a potentially modifiable condition, both 
pharmacologically and non-pharmacologically  [33]. 
The high level of dissatisfaction with the diagnostic process 
and treatment options provided by practitioners observed here is 
not an isolated finding in JHS/EDS-HT-related research. Qualitative 
research has revealed that individuals with a diagnosis of JHS gen- 
erally feel that their condition is poorly understood, and many 
report  lengthy  delays  in  obtaining  a  diagnosis  [37].  Patients 
diagnosed with EDS have also described experiences with health 
professionals that have left them feeling ignored and on some 
occasions, they report being assigned psychiatric or psychological 
explanations for their symptoms, with resultant anxiety concern- 
ing the management of their condition [38]. 
The acceptance of JHS/EDS-HT as a pathological and multisys- 
tem disorder is a potential obstacle to appropriate diagnosis and 
management. One study found that only 39% of UK rheumatolo- 
gists recognized hypermobility syndrome (synonymous with JHS) 
as a pathological entity, only 6% of respondents considering non- 
articular signs in its diagnosis [39]. Another study reported less 
than 25% of USA physical therapists considered JHS to be a sys- 
temic condition with only 13% identifying fatigue as a significant 
feature of the condition [40]. Only 36% of these therapists utilized 
the Beighton score and 27% used the Brighton criteria [40]. The 
knowledge and beliefs of health care practitioners relating to the 
tools utilized in the diagnosis of JHS/EDS-HT and the presence of 
non-articular signs and symptoms associated with the disorder, 
highlight an opportunity for education of medical and allied 
health students and practitioners regarding the condition, thereby 
facilitating the development of timely and appropriate manage- 
ment plans. A reduction in the lengthy delay that many patients 
experience in obtaining a diagnosis and an improvement in the 
specificity of subsequent management options may improve 
patients’ overall satisfaction with the diagnosis, treatment and 
management options provided by practitioners, and thereby have 
some impact on their fatigue. 
The psychological symptoms evident in the current cohort are 
comparable with those reported by patients seeking tertiary pain 
management services for chronic pain [15]. Previous research has 
identified that individuals with JHS/EDS-HT have higher incidences 
of anxiety, depression, panic-agoraphobia and resultant utilization 
of anti-anxiety medication compared to non-affected individuals 
[41]. The current study found a significant association between 
psychological symptoms and fatigue. It is, however, pertinent to 
acknowledge that the multiple regression analysis applied to the 
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current cohort did not find that psychological factors relating to 
depression predicted fatigue severity. 
It is relevant to consider the generalizability of the results of 
this study to the population of persons with JHS/EDS-HT. The ratio 
of female to male participants was high; however, this reflects the 
gender imbalance commonly seen clinically in this population. 
The study protocol, recruiting participants through two online 
support group websites, may have resulted in sampling bias. It is 
possible that the members of such a group do not fully represent 
the entire population of people diagnosed with the condition. A 
further limitation of all research on JHS/EDS-HT is the lack of clear 
diagnostic criteria. 
The results of the current study highlight directions for 
improvements in the diagnosis and management of individuals 
affected by JHS/EDS-HT, and in particular the management of 
fatigue, a significant feature of the disorder. The identification of 
four potentially modifiable predictors of fatigue suggests the ben- 
efits of screening of individuals with JHS/EDS-HT for fatigue and 
assists in the selection of management options for symptoms and 
signs shown to determine fatigue severity. Identification of modifi- 
able predictors of fatigue will assist with early referral to appropri- 
ate health practitioners. The findings of the current study support 
the future inclusion of management strategies to address; levels 
of physical activity participation (physiotherapists and exercise 
physiologists); coping strategies to improve participation in com- 
munity and family interactions (clinical psychologists) and investi- 
gation and management of orthostatic intolerance (cardiologists). 
Given the inadequate recognition of the condition by health pro- 
fessionals, professional education particularly for primary practi- 
tioners (including but not limited to rehabilitation specialists, 
geneticists and rheumatologists) regarding the complex diagnosis 
of the disorder and the scope of potential management strategies, 
may assist in the management of fatigue severity in this popula- 
tion. The combination of predictors identified highlights the need 
for a multidisciplinary approach to optimize the management   of 
[2] Tinkle B, Castori M, Berglund B, et al. Hypermobile 
Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome 
Type III and Ehlers–Danlos syndrome hypermobility type): 
clinical description and natural history. Am J Med Genet C 
Semin Med Genet. 2017;175:48–69. 
Grahame R, Bird HA, Child A. The revised (Brighton 1998) 
criteria for the diagnosis of benign joint hypermobility syn- 
drome (BJHS). J Rheumatol.  2000;27:1777–1779. 
Beighton P, De Paepe A, Steinmann B, et al. Ehlers–Danlos 
[3] 
[4] 
syndromes: revised nosology, Villefranche, 1997. 
and 
Genet. 
Ehlers–Danlos National Foundation (USA) 
Ehlers–Danlos Support Group (UK). Am J Med 
1998;77:31–37. 
[5] Tinkle BT, Bird HA, Grahame R, et al. The lack of clinical dis- 
tinction between the hypermobility type of Ehlers–Danlos 
syndrome and the joint hypermobility syndrome (a.k.a. 
hypermobility syndrome). Am J Med Genet A. 2009;149A: 
2368–2370. 
Malfait F, Hakim AJ, De Paepe A, et al. The genetic basis of 
the joint hypermobility syndromes. Rheumatology (Oxford). 
2006;45:502–507. 
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and its underlying mechanisms in the hypermobility type 
of Ehlers–Danlos syndrome. Semin Arthritis Rheum. 
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drome subclassification in paediatrics: a factor analytic 
approach. Arch Dis Child. 2015;100:8–13. 
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Voermans NC, Knoop H, Bleijenberg G, et al. Fatigue is 
associated with muscle weakness in Ehlers–Danlos syn- 
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the overall management of this condition 
Conclusion 
The current findings regarding JHS/ED-HT can direct practitioners 
towards potential interventions that may help to improve an indi- 
vidual’s fatigue levels and as a consequence, their health-related 
quality of life. Further research will determine if the identification 
and management of the recognized predictors of fatigue can, in 
fact, result in decreased fatigue severity in this population. 
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Study 2: Features that determine Health-Related Quality of Life 
in individuals affected by Joint Hypermobility 
Syndrome/Ehlers-Danlos Syndrome-Hypermobility Type. 
 
A paper based on the study in this chapter will be submitted for consideration for publication. 
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Features that determine Health-Related Quality of Life in individuals 
affected by Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome-
Hypermobility Type. 
Abstract:  
Aims: 
To identify the features of Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome-
Hypermobility Type (JHS/EDS-HT) that are associated with Health-Related Quality 
of Life (HRQoL) and to determine if there are modifiable predictors of HRQoL in this 
condition for which targeted management strategies could be developed.  
Methods: 
In a cross-sectional study of individuals affected by JHS/EDS-HT, questionnaires 
were used to obtain information on; symptoms and signs related to JHS/EDS-HT, 
fatigue, HRQoL, mental health, physical activity participation and sleep quality. 
Multiple regression analysis was performed to identify predictors of HRQoL in this 
population.  
Results: 
HRQoL obtained using the Assessment of Quality of Life-6 Dimension measure was 
significantly reduced in the 106 participants with JHS/EDS-HT, compared to 
normative data.  HRQoL was significantly correlated with a range of manifestations 
of JHS/EDS-HT.  Of these, fatigue was found to have the strongest relationship with 
overall HRQoL (r = -0.712, p < 0.005), while depression, anxiety, current levels of 
physical activity participation, the number of cardiac/vascular manifestations and 
number of joints affected by pain were all moderately correlated with HRQoL.  With 
the moderately correlated features entered as independent variables, multiple 
regression analysis identified that the number of joints affected by pain, the current 
level of physical activity and depression symptoms were predictive of 54.9% of the 
overall variance in HRQoL reported by participants of the study. 
Conclusion: 
Overall HRQoL is significantly lower than normal in individuals with JHS/EDS-HT.  
Information about the key contributors to HRQoL in this condition gives clinicians 
and researchers options for future investigation of interventions aimed at improving 
the lived experience of those affected by the disorder. 
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Introduction: 
Ehlers-Danlos Syndrome – Hypermobility Type (EDS-HT) and Joint Hypermobility 
Syndrome (JHS) are connective tissue disorders where joint hypermobility is a major 
diagnostic feature.  Despite being diagnosed using different criteria, EDS-HT by the 
Villefranche Criteria (1) and JHS by the Brighton Criteria (2), the two conditions are 
increasingly referred to as indistinguishable (3, 4) (Table 4.1).  Musculoskeletal 
symptoms, such as joint hypermobility, instability, and arthralgia, form the basis of 
the diagnostic criteria for the conditions, however individuals affected by the disorder 
can experience a range of systemic symptoms, including gastrointestinal (5) and 
autonomic nervous system dysfunction (6), fatigue (7-10), mental health conditions, 
anxiety and depression (11), and genitourinary complaints (12).    
 
Historically, there has been a disconnection between the experience of individuals 
affected by JHS/EDS-HT and the infrequent recognition by the involved health 
professions of the condition as a systemic multidimensional disorder, rather than as an 
isolated musculoskeletal condition (13, 14). With increasing research on the features 
of JHS/EDS-HT, it is becoming clear that the condition not only has significant 
musculoskeletal and systemic manifestations, but also has a significant detrimental 
effect on health-related quality of life (HRQoL) (15), causing substantial disease-
related morbidity (16).  
 
Research has demonstrated that both the paediatric and adult populations affected by 
JHS/EDS-HT have globally-reduced HRQoL.  Specific associations have been drawn 
between HRQoL and systemic features including fatigue (17-19), mental health (20), 
genitourinary (12, 21) and autonomic dysfunction (10), and gastrointestinal symptoms 
(22). The overall burden of the disease in the adult population of JHS has been found 
to be similar to that in patients affected by Fibromyalgia, and greater than that for 
individuals diagnosed with Rheumatoid Arthritis (23). Research focusing on JHS in 
the paediatric population has identified the severity of pain, fatigue, and stress 
incontinence as predictors of HRQoL (24).  There is a need to replicate and extend 
this research to the adult population in order to appropriately identify and manage 
factors that contribute to HRQoL and potentially decrease the burden of the disease 
on both the individual and the community.    
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Given the multifactorial nature of JHS/EDS-HT, any single intervention is unlikely to 
significantly improve overall HRQoL. Therefore, the aims of this study were to 
identify the features of JHS/EDS-HT that are associated with HRQoL and to 
determine if there are modifiable predictors of HRQoL in this population, to enable 
the development of targeted management strategies. 
Table 4.1 Diagnostic criteria for EDS-HT and for JHS   
Villefranche Criteria for  EDS-HT (1) JHS – Brighton Criteria (2) 
Major Criteria  
3. Beighton ≥ 5/9 
4. Skin involvement (hyper extensibility and/or 
smooth, velvety skin) 
Minor Criteria  
4. Recurring joint dislocations 
5. Chronic joint or limb pain  
6. Positive family history  
 
Major criteria 
3. Beighton ≥ 4/9 
4. Arthralgia for > 3 months in ≥4 joints 
Minor criteria: 
9. Beighton score 1-3/9 if  >50yrs old 
10. Arthralgia > 3 months in 1-3 joints or back pain >3 
months 
11. Dislocation/subluxation in > 1 joint or in one joint 
on more than one occasion 
12. Soft tissue rheumatism ≥  3 lesions 
13. Marfanoid habitus 
14. Abnormal skin: striae, hyper extensibility, thin skin, 
papyraceous scarring  
15. Eye signs: drooping eyelids or myopia or 
antimongoloid slant  
16. Varicose veins or hernia or rectal or uterine prolapse 
Diagnosis of EDS-HT suggested when: 
One or more of the major criteria present. 
Minor criteria points differentiate between subtypes of 
EDS but are not sufficient in the absence of major criteria 
findings for a diagnosis of EDS-HT.  
JHS is diagnosed in presence of  
5. Two major criteria 
6. One major and two minor criteria  
7. Four minor criteria  
8. Unequivocally affected first degree relative 
in the absence of Marfan or EDS (other than EDS-HT) 
 
Methods: 
A cross-sectional cohort study was undertaken. Recruitment of adult participants (16-
65 years of age) was undertaken by advertising on Australian based EDS websites 
(ConnecTed and EDSAUS) and by word of mouth. Participants were recruited 
between 2012 and 2014. Individuals with a pre-existing diagnosis of Marfan 
Syndrome, Osteogenesis Imperfecta, Ehlers-Danlos Syndrome (Type I, II or IV), 
Stickler’s disease or Loeys-Dietz Syndrome were excluded from the study. 
Participants were included in this study if they had a diagnosis of either JHS or EDS-
HT.  Once volunteers were consented to participate in the study, a questionnaire was 
submitted and returned by mail or email. Any responses that were not clear were 
addressed in further email communication or by phone. The University of Sydney’s 
Human Research Ethics Committee granted ethical approval to conduct this research 
(Protocol number 2012/558). 
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Self-Report data: 
All participants completed the questionnaire component of the study, providing 
demographic data and information relating to symptoms associated with JHS/EDS-
HT.  This included data relating to the presence of joint pain and instability, muscle 
pain, fracture history, connective tissue/cutaneous features, urinary incontinence 
(measured on a visual analogue scale (VAS) where 0= never leaking urine on 
cough/jump to 100 = often leaking urine) and dysautonomia symptoms related to the 
cardiovascular (Postural Orthostatic Tachycardia syndrome, orthostatic intolerance, 
orthostatic palpitations, fatigue and dizziness) (16, 25, 26) and gastrointestinal 
systems (nausea, diarrhoea, constipation, dysmotility of the gastointestinal tract) (27, 
28).  Orthostatic dizziness was measure on a VAS ((0 = “never” and 100 = “often” 
experiencing dizziness associated with heat/change in position/participation in 
exercise). Information regarding co-morbid medical conditions, previous surgery and 
sleep quality and duration was also recorded. Structured questionnaires were used to 
ascertain HRQoL, current mental health status, self-perceived joint hypermobility, 
physical activity participation and fatigue severity.  
  
Health Related Quality of Life: 
To establish self-reported HRQoL the AQoL-6D, a six dimension, 20-item instrument 
was used. The dimensions measured by the instrument include independent living, 
mental health, coping, relationships, pain and senses (i.e. 
sight/smell/touch/hearing/taste). Each dimension is scored between 0.0 and 1.0, where 
a higher score indicates greater perceived HRQoL (29).  Adult population normative 
data is available for comparison (29). 
 
Mental Health: 
The Depression Anxiety Stress Scale 21 (DASS-21) was used as an indicator of the 
psychological wellbeing of each participant. The DASS-21 is a 21-item, self-report 
tool incorporating the three dimensions of depression, anxiety and stress. Each 
dimension is assessed with 7 questions; the score range possible for each dimension is 
0-21. The total score range for the combined dimensions is 0-63. To interpret the 
severity of each dimension, individual scores are doubled to enable use of DASS-42 
normative data, allowing the comparison of symptom severity to “normal” in each 
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category (30). A higher score indicates poorer mental health. 
 
Physical Activity: 
Current level of physical activity participation was measured using the Physical 
Activity Index (PAI), giving a composite score, with three individual components; 
Intensity (1-5), Duration (1-4) and Frequency (1-5).  The total score was calculated 
using the equation, Intensity x Duration x Frequency = Total Score /100, with activity 
participation classified as; sedentary (<20), poor (20-39), fair (40-59), very good (60-
80) and high (81-100) (31). 
 
Self-perceived Hypermobility: 
The Hakim 5-part questionnaire (32) is a 5 item self-report tool for identifying 
historical generalized joint hypermobility (GJH).  A score of ≥2/5 is required for a 
diagnosis of GJH, and this has 84% diagnostic accuracy (32). 
 
Fatigue 
Fatigue severity was assessed using the Fatigue Severity Scale (FSS) (33), a nine 
item, self-report scale with a score range of 9 – 63, whereby higher scores represent 
greater levels of fatigue. The mean individual score was utilized to compare values to 
normative FSS data (healthy adult population) (33, 34) and FSS mean scores reported 
in JHS literature (35).  A mean FSS individual score of ≥4/7 (34) or a total score of 
≥36/63 (33) are accepted as the cut-off values indicating the presence of significant 
fatigue. 
 
Sleep measures: 
Sleep quality and quantity (hours/night) was measured using a set of specific 
questions and the creation of a composite score to quantify overall sleep quality. The 
questions contributing to the composite score were; does discomfort relating to your 
joint hypermobility wake you, are you un-refreshed on waking, do you snore, do you 
experience difficulty getting to sleep, if so does it take longer than 20min.  Each 
positive response was allocated 1 point with a maximum score of 5/5 possible, with 
higher scores indicating reduced self-reported sleep quality.  
 
Statistical analysis: 
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SPSS (Version 23) was utilized for data analysis.  Descriptive statistics were used to 
define the study sample and independent t-tests were used to compare means of 
AQoL-6D normative data (29) with those of the study population.  Correlation 
analysis was performed using Pearson’s Coefficient (r) to determine the extent of the 
relationship between variables. Stepwise multiple regression analysis was performed, 
with the AQoL-6D mean total score as the dependent variable, and eight variables 
representing dimensions of JHS/EDS-HT likely to affect HRQoL entered as 
independent variables. The variables identified in the final model of the Multiple 
Regression Analysis (stepwise method; probability of F in at 0.05 and out at 0.10) 
were viewed as predictors of HRQoL in the study population.  Level of significance 
was set at a probability (p) value of less than 0.05. 
 
Results: 
Participants: 
One hundred and six individuals (99 female, 7 male), with a mean (SD) age of 35.64 
years (11) met the inclusion criteria and participated in the study (see figure 4.1). 
Characteristics of the study population can be found in Table 4.2.  The specific 
diagnosis was EDS-HT in 68% and JHS in 25% of study participants, while 7% 
reported both diagnoses. The prevalence of dissatisfaction with the diagnostic process 
and management options they were provided was 61.4% of the cohort.  
 
 
Figure 4.1 Study Population flow chart 
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Table 4.2 Reported features associated with JHS/EDS-HT 
 Mean (SD) 
Hakim 5 (/5) (n =106) 3.8 (1.2) 
No. Painful Joints (n =106) 10 (5.0) 
No. JHS/EDS-HT related Surgeries (n =105) 1.7 (3.) 
Individual FSS (n =106) 5.5 (1.6) 
PAI total score (n =106) 24.5 (20.5) 
Hours Sleep/night (n =103) 6.9 (2.1) 
DASS Depression (/42) (n =106) 10 (8.6) 
DASS Anxiety (/42) (n =106) 9.3 (7.2) 
DASS Stress (/42) (n =106) 15.7 (9.1) 
 
Disease specific data: 
Polyarthralgia (≥ 4 painful joints) was present in 88.7%, while soft tissue pain 
affecting ≥ 3 regions was present in 46.2% of respondents.  Non-musculoskeletal 
features of the Brighton Criteria included hernias in 25.5% and genitourinary prolapse 
in 3.8% of participants, skin abnormalities in 44% (e.g. thin/stretchy/abnormal 
scarring) and 45.7% of participants reported being shortsighted.   
 
Self-reported urinary incontinence, measured on a visual analogue scale, revealed a 
mean (SD) of 36.9 (34.5) while 3.7% of the cohort had undergone surgery for 
genitourinary conditions.  
 
The prevalence of systemic and musculoskeletal features associated with the disorder 
are presented in Figure 4.1. Significant fatigue was present 81% of the cohort and was 
the most prevalent systemic feature of the disorder, second only to arthralgia as the 
most widespread of all manifestations of JHS/EDS-HT in this population.  Features of 
autonomic dysfunction relating to the cardiovascular system were present in 30.5% of 
participants, with 17.1% having a specific medical diagnosis of Postural Orthostatic 
Tachycardia Syndrome, while the mean (SD) VAS score for dizziness was 74.2 
(28.9). Gastrointestinal symptoms (e.g. regular diarrhoea/ constipation / stomach 
upset including diagnoses of gastroparesis /Irritable Bowel Syndrome /Crohn’s 
disease) were reported by 28.6% of the cohort.  
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Figure 4.2 Prevalence of musculoskeletal and non-musculoskeletal manifestations of 
JHS/EDS-HT. 
The mean DASS-21 depression, anxiety and stress dimension scores are reported in 
Table 4.2, while the frequency of each dimension and severity of symptoms reported 
by participants can be found in Figure 4.2. Analysis of the subscales of the DASS-21 
revealed the severity of symptoms reported in each dimension.  On the depression 
subscale, 18% had mild, 18% had moderate, 6% reported severe and 6% recorded a 
severity of depressive symptoms, which placed them in the extremely severe 
category.  Anxiety symptom levels were reported as mild by 10%, moderate in 23%, 
severe in 11% and extremely severe in 8.6% of respondents. Symptom levels in the 
stressed categories were reported as mild by 12%, moderate in 15%, severe in 13.3% 
and extremely severe in 4.8% of respondents. 
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Figure 4.3 Prevalence and severity of symptoms relating to Depression (n =106), Anxiety 
(n =106)  and Stress (n =106)  
 
Questions relating to sleep patterns revealed that 91.4% of participants felt un-
refreshed on waking, 73.3% were awoken by discomfort, 38.8% snored and 67.6% 
experienced difficulty getting to sleep. The mean (SD) composite score for sleep 
quality was 3.4 (1.3) with higher scores out of a possible 5 representing poorer sleep 
quality. 
 
The current level of physical activity participation measured using the PAI revealed 
that 51.9% of the cohort were classed as sedentary, 28.3% had poor, 8.5% fair, 10.4% 
very good and 0.9% high participation, using the composite PAI score.  Lifetime 
participation in sporting activities showed that 26.4% of participants had not 
participated in any sport continuously for a minimum of one season.  
 
HRQoL was significantly reduced across all dimensions of the AQoL-6D, when 
compared to normative data (29) at a significance level of p<0.05 using the 
independent T-Test to compare means (Table 4.3).  The total AQoL score, along with 
the individual dimensions of the instrument, were correlated with manifestations of 
JHS/EDS-HT (Systemic and Musculoskeletal), mental health findings, sleep quantity 
and quality and incontinence (Table 4.4). The three strongest correlations with the 
AQoL total scores were with fatigue (FSS individual scores), depression symptoms 
(DASS-21) and activity level (PAI composite score). 
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Table 4.3 Comparison of AQoL 6D study data to normative values (29) 
 Current Study 
Mean values (SD) 
N= 106 Mean (SD) 
Normative mean 
values (29) (SD)          
N= 2731 
T- test P value 
95%CI  
AQoL 6D Total 0.61 (0.14) 0.84 (0.12) <0.0001* 
Independent Living 0.64 (0.22) 0.93 (0.13) <0.0001* 
Relationships 0.68 (0.19) 0.90 (0.13) <0.0001* 
Mental Health  0.59 (0.15) 0.75 (0.17) <0.0001* 
Coping 0.50 (0.17) 0.75 (0.18) <0.0001* 
Pain  0.41 (0.22) 0.86 (0.20) <0.0001* 
Senses 0.81 (0.19) 0.88 (0.11) <0.0001* 
 
 76 
Table 4.4 Correlations (Pearson’s r) between the AQoL-6D total score and the 6 individual dimensional scores with manifestations of the JHS/EDS-
HT. 
 AQoL - Total 
Score 
AQoL - 
Independent 
Living  
AQoL -
Relationship  
AQoL -Mental 
Health  
AQoL - 
Coping  
AQoL - Pain 
 
AQoL - Senses 
Hakim 5 
n = 106 
-0.270** -0.207** -0.148 -0.202* -0.212* -0.232* -0.239* 
No. of joints affected by pain  
n = 106 
-0.474** -0.386** -0.339** -0.237* -0.207* -0.583** -0.437** 
PAI Total Score 
n =106 
0.491** 0.458** 0.426** 0.318** 0.451** 0.352** 0.140 
Incontinence VAS 
n = 105 
-0.257** -0.167 -0.258** -0.177 -0.127 -0.250* -0.264** 
Cardiovascular  
Manifestations 
n = 105 
-0.368** -0.333** -0.348** -0.212* -0.304** -0.150 -0.352** 
Gastrointestinal features 
(number of features 
reported) 
n = 105 
-0.143 -0.197* -0.168 0.027 -0.018 -0.118 -0.140 
Mean Individual FSS 
n =106 
-0.712** -0.629** -0.645** -0.422** -0.594** -0.556** -0.335** 
Average hours sleep/night 
n = 103 
0.028 -0.077 -0.173 0.174 -0.015 0.149 0.136 
Sleep Quality (composite 
score)  
n = 103 
-0.241* -0.209* -0.123 -0.189 -0.105 -0.310** -0.118 
Depression –  
DASS-21 
n =106 
-0.484** -0.255** -0.392** -0.691** -0.556* -0.202* -0.149 
Anxiety –  
DASS-21 
n =106 
-0.461** -0.328** -0.352** -0.382** -0.444** -0.305** -0.337** 
Stress –   
 DASS-21 
n =106 
-0.297** -0.061 -0.151 -0.583** -0.373** -0.175 -0.085 
* Indicates p≤0.05, ** indicates p≤0.005
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Prediction of QoL: 
Stepwise multiple regression analysis was performed to assess the impact of 
manifestations of JHS/EDS-HT on the overall HRQoL of the cohort.  The eight 
independent variables entered into the multiple regression analysis were:  Self-
perceived hypermobility (Musculoskeletal), number of joints affected by pain 
(Musculoskeletal), Dizziness (Systemic), Incontinence (Systemic), Gastrointestinal 
involvement (Systemic), physical activity level (Functional), Depression (Mental 
Health) and sleep duration, reflecting significant manifestations of the disorder.  To 
enable a clearer interpretation of the influence of these variables on HRQoL, fatigue 
was not included in the analysis as it has previously been established as an influence 
on HRQoL (19). The multiple regression analysis retained three variables; DASS-21 
Depression Score (Beta -0.412, p < 0.001), number of joints affected by pain (Beta -
0.410, p < 0.001) and level of current physical activity (Beta 0.291, p < 0.001) ( with 
the following regression equation accounting for 54.9% (Adjusted  = 0.549, SE of 
the estimate = 0.093, F value 41.13 (p <0.0001)) of the variance in the total AQoL-6D 
score: 
 
AQoL-6D Total Score = 0.746 – (0.07 x DASS-21 Depression score) – (0.11 x no. of 
painful joints) + (0.002 x PAI Physical Activity)  
 
With an inverse relationship between DASS-21 Depression scores and the number of 
joints affected by pain and the overall AQoL score, the regression equation shows that 
with increasing scores both on DASS-21 and for the number of joints affected, overall 
QoL decreases.  Physical activity had a direct relationship with AQoL scores, with 
increasing participation in activity predictive of improved overall HRQoL.  
 
Discussion: 
This adult JHS/EDS-HT cohort reported a significantly lower health-related quality of 
life than that reported by a healthy population.  Each dimension of the AQoL 
demonstrated significantly lower scores, revealing a global effect of the disease on 
HRQoL. The results of the current study indicated that, in addition to connective 
tissue features, systemic and mental health manifestations of the condition and level 
of physical activity have significant associations with HRQoL.  This is the first study 
to identify potential predictors of HRQoL in an adult cohort affected by JHS/EDS-
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HT, taking into account the overall profile of the disorder. Three potential predictors 
of HRQoL were identified, and these stand in addition to fatigue severity, which has 
previously been documented as a significant symptom of the disorder that can be 
predicted by aspects of AQoL-6D tool (19). Specifically, the extent of depressive 
symptoms as measured using the DASS-21, the total number of joints affected by 
pain and the current level of physical activity participation were predictive of overall 
HRQoL as reported by participants, thereby accounting for 54.9% of variance in the 
AQoL-6D total instrument scores.  
 
The findings of this study support and extend those of previous research in JHS(18), 
EDS (involving all subtypes) (36) and EDS-HT (15) demonstrating significantly 
reduced HRQoL in individuals affected by the disorder compared to controls.  
Rombaut et al (2010) found, using the Rand 36-Item Health Survey tool,  
that participants with EDS-HT (N=32) had significantly lower HRQoL compared to 
controls in the domains of physical functioning, social functioning, limitations due to 
physical problems, limitations due to emotional problems, mental health, vitality, 
bodily pain, general health perception and physical component summary (15). 
Similarly, Albayrak et al (2015) found that individuals affected by Benign Joint 
Hypermobility Syndrome (a term they used synonymously with JHS) reported 
significantly reduced HRQoL using the Short Form 36 in the subscales of physical 
function, role physical, bodily pain, general health, role emotional and mental health.  
Additionally, these researchers found significantly higher depression scores, worse 
quality of sleep and greater fatigue when compared to matched controls (18), although 
the generalizability of their findings of this study is somewhat compromised by their 
exclusion criteria that limited the cohort studied to those least affected by the 
condition (18).  The design of the current study, with a cohort size of 106 JHS/EDS-
HT participants, including all levels of disease severity, allows for greater 
generalization of the results and increases the breadth of existing knowledge relating 
to the impact of the disorder on HRQoL.  
 
Historically, health professionals have viewed JHS/EDS-HT as a condition that has 
minimal morbidity, primarily affecting the musculoskeletal system (37, 38). Only 
recently has the condition been recognized clinically as a multisystem disorder.  It is 
therefore of particular interest that overall HRQOL in the current cohort could be 
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predicted by the severity of depressive symptoms and current physical activity 
participation, in addition to the number of joints affected by pain. Fatigue severity has 
already been identified as the most prevalent systemic symptom in this cohort, second 
only to polyarthralgia, and is strongly correlated with overall HRQoL.  
 
Reduced physical activity has consistently been identified in paediatric (27, 39, 40) 
and adult (15, 41) populations affected by JHS/EDS-HT, for whom previous research 
has documented significantly lower sports participation (15), reduced mobility 
associated with muscle weakness (41), and reduced lower limb strength and 
endurance compared to unaffected individuals (42).  Kinesiophobia, resulting in fear 
avoidance of movement, has been documented in JHS/EDS-HT and correlated with 
fatigue severity (35).  Kinesiophobia has previously been identified as a possible 
mechanism for the progression from acute to chronic pain and is hypothesized to play 
a significant role in the progression to disability seen in JHS/EDS-HT (16, 43, 44), 
likely due to the resultant deconditioning as a result of reduced physical activity. The 
current study identified that while the majority of participants (73.8%) had taken part 
in at least 1 season of sport during their lifetime, at the time of the study the mean PAI 
total score placed the cohort in the “poor” category for physical activity. The evidence 
suggests that individuals affected by JHS/EDS-HT report reduced physical activity 
and likely have lower muscle strength and endurance compared to the general 
population, which provides the opportunity for clinicians to develop and test graded 
disease-appropriate exercise programs, and to implement strategies to manage 
kinesiophobia in order to address this aspect of the disorder.  
 
Individuals affected by JHS/EDS-HT have previously been reported to have a higher 
incidence of anxiety, depression and use of anti-anxiety medication compared to the 
general public (11).  The present study has shown that the overall HRQoL 
experienced by participants was moderately to strongly correlated with depression, 
anxiety and stress symptoms as measured using the DASS-21(45).  These findings are 
consistent with a recent study that identified 74.8% of adult individuals diagnosed 
with EDS-HT scored high for anxiety symptoms while 22.4% scored high on 
depression symptoms (36). The overall psychological symptoms reported here are 
similar to those seen in patients seeking tertiary management of chronic pain (46). 
The possible reasons for the elevated reports of psychological comorbidities in this 
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population are likely to be multifactorial, including but not limited to; the delay in 
diagnosis/misdiagnosis of the disorder, poor professional recognition and 
understanding of JHS/EDS, the disparity between the experience of individuals with 
JHS and how health practitioners perceive the severity and impact of the disease on 
suffers (47), the experience of recurrent joint dislocations and injuries, chronic pain, 
elevated fatigue levels and the non-musculoskeletal features of the disorder (48). The 
results here provide further evidence that the psychological wellbeing of individuals 
affected by JHS/EDS-HT has a potentially significant impact on the overall burden of 
the disorder and warrants monitoring and management in those identified as being at 
risk of mental health manifestations.  
 
Despite previous research demonstrating associations between urinary incontinence 
(adult (12) and paediatric populations (24)) and pelvic organ prolapse symptoms (21), 
with HRQoL, the current study identified only a weak association between increasing 
frequency of urinary incontinence (p<0.005) and overall quality of life.  Only 7.7% of 
participants reported urinary incontinence or pelvic organ prolapse (UI/POP) 
(genitourinary features in Figure 4.1) and these features were not found to predict of 
the overall HRQoL in the multiple regression analysis. It has previously been 
identified that those affected by JHS/EDS-HT have an increased incidence of 
symptoms associated with UI/POP compared to the general population without 
necessarily causing the individuals significant concern (21).  Their apparent lack of 
concern may result in affected individuals failing to seek professional assistance 
leading to a formal diagnosis of UI/POP, and highlights the need to include structured 
questionnaires in clinical practice relating to UI/POP symptoms to optimize 
management of the disorder.  
 
As HRQoL is an indicator of the overall impact of a disorder on an individual, the 
identification of depressive symptoms, physical activity participation and number of 
joints affected by pain, in addition to fatigue severity as all being significant 
contributors to HRQoL, suggests that the development of management strategies 
targeting these factors is critical in any attempt to improve the lives of those affected 
by JHS/EDS-HT.  Physical activity levels and psychological wellbeing have 
previously been identified as interconnected features in health related research, with 
both inactivity associated with poorer mental health and increased activity 
 81 
participation associated with improvements in psychological conditions such as 
depression and anxiety (49).  It has been established that physical activity, used as an 
intervention for depression, has a moderate affect on depression levels, and may be as 
effective as psychological and pharmacological interventions targeting depression 
(50).  It is therefore probable that the reduced physical activity participation seen in 
JHS/EDS-HT plays a role in the development and/or maintenance of reduced 
psychological wellbeing. Accordingly, interventions aimed at increasing physical 
activity are likely to see a dual effect, improving both physical activity and depression 
symptoms. 
 
No studies have as yet determined the efficacy of pain management strategies, 
involving cognitive behavioral therapy (CBT), implemented to address kinesiophobia, 
coping strategies and psychological manifestations, and graded physical activity 
participation to improve the HRQoL of adults with JHS/EDS-HT. CBT in a pain 
management setting has been shown to improve self-efficacy, depression and anxiety 
measures, reduce pain severity and catastrophising, and overall impact of the disorder 
on daily life, however HRQoL and fatigue levels were not incorporated into the 
objective measures of this study (51).   Another study, which investigated the benefit 
of CBT and structured exercise programs, demonstrated that the intervention was 
successful in decreasing levels of kinesiophobia and increasing functional measures 
but did not employ psychological or direct measures of HRQoL (52) as outcome 
measures.  However, a home based exercise programs have demonstrated significant 
improvements in the HRQoL of both children and adults with JHS/EDS-HT following 
completion of the intervention (53, 54). The use of incremental exercise programs 
utilizing exercise based quotas is a proven strategy to increase levels of physical 
activity in a graded and sustained manner in those affected by chronic pain (55).  
Although this method has not been specifically investigated in JHS/EDS-HT literature 
it seems likely that such an approach would be advantageous in increasing the activity 
levels of the JHS/EDS-HT population. It appears likely from the research currently 
available that a combination of a specific graded exercise program, and pain 
management strategies involving CBT would help to improve overall HRQoL, 
however, to confirm the efficacy of such a program in individuals with JHS/EDS-HT, 
further research is necessary. This would determine if management strategies 
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designed to manage pain, improve physical activity and address psychological 
manifestations in this population can indeed improve HRQoL.  
 
The results of the current study suggest important avenues for further management of 
JHS/EDS-HT for both clinicians and researchers.  The identification of significant 
systemic manifestations, such as severe fatigue and psychological symptoms in 
addition to musculoskeletal features of the disorder as contributing to overall HRQoL, 
emphasizes the importance of acknowledging the systemic nature of the disorder in 
the assessment and management of individuals diagnosed with JHS/EDS-HT. As 
anticipated, no single feature of the disorder adequately explained the variability in 
HRQoL as a result, it is unlikely that interventions aimed at a single aspect of the 
disorder would successfully improve HRQoL.  This study provides a basis for 
advances in clinical practice, and should prompt research to determine the efficacy of 
management strategies combining psychological interventions, aimed at both pain 
management and psychological manifestations of the disorder, and physiotherapy, 
aimed at increasing physical activity participation, to jointly help reduce the impact of 
JHS/EDS-HT on the overall HRQoL of individuals affected by the disorder.  
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Chapter Five 
Conclusion and Future Directions 
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Synopsis of findings: 
The results of the current study are in agreement with previously published literature 
in demonstrating the complex, multi-system nature of JHS/EDS-HT(9, 133, 134).  In 
addition to the identification of a range of musculoskeletal manifestations of the 
condition, such as joint and muscle pain, history of dislocations and surgery for 
connective tissue features of the disorder, the current study has identified an array of 
systemic manifestations that are highly prevalent and associated with the overall 
quality of life experienced by those affected by the disorder.   
 
A primary aim of this thesis was to investigate the prevalence, severity and impact of 
fatigue on individuals diagnosed with JHS/EDS-HT.   The results indicate that fatigue 
is not only a frequently occurring manifestation of JHS/EDS-HT but it is strongly 
associated with reduced overall HRQoL.  In the current sample of 117 adults with the 
condition, clinically significant fatigue was present in 79.5%, representing the most 
prevalent of all the non-musculoskeletal manifestations associated with the disorder.  
The levels of fatigue reported using the FSS scale (Appendix 3) indicate that its 
severity is comparable to that experienced in a range of systemic conditions, including 
MS, SLE and RA (102), where fatigue is a well-recognized manifestation of these 
disorders.  The overall prevalence of significant fatigue found in this population 
mirrors previous results from studies in non-differentiated EDS cohorts, and from 
smaller JHS/EDS-HT-specific studies (8, 57, 59, 105).   With the presence of fatigue 
previously identified as being associated with pain and aspects of quality of life (8, 
60), and ranked as the most detrimental systemic manifestation in terms of QoL (9), 
the importance of identifying potential predicators was recognised.  Five features of 
JHS/EDS-HT were found to predict the severity of fatigue in the current study cohort, 
accounting for 52.3% of the variance in the FSS mean score.  Of the five potential 
predictors of fatigue severity, four were identified as being modifiable with 
appropriate investigation and intervention.  The four modifiable predictors of fatigue 
severity were; orthostatic dizziness, participation in personal relationships and 
community, participation in physical activity, and satisfaction with the medical 
management and treatment options offered by health professionals.   The successful 
identification of possible determinants of fatigue severity provides the opportunity for 
targeted investigation and management of individuals with JHS/EDS-HT.  Fatigue 
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severity increased with the increased experience of orthostatic dizziness, the reduction 
in participation in physical activities and personal and community relationships, while 
dissatisfaction with the diagnostic process and subsequent management options 
increased fatigue severity.  
 
HRQoL had previously been identified, in both non-differentiated EDS samples (60, 
135) and in specific research relating to JHS/EDS-HT (86, 126), as being reduced 
compared to normative data. The evaluation and determination of potential predictors 
of overall HRQoL was therefore a primary aim of this thesis.  HRQoL in the current 
cohort was significantly reduced across all domains measured using the AQoL – 6D 
tool (Appendix 4).  The greatest differences between normative data and the results of 
the current cohort were seen in the domains of pain, independent living and aspects of 
coping.  As fatigue was identified in the first study here as being predicted by the 
relationship domain of an individual’s quality of life, it was excluded from the 
subsequent multiple regression analysis carried out to identify potential determinants 
of HRQoL.  In the current cohort, it was identified that 55% of the variance in the 
overall HRQoL, as measured using the AQoL – 6D tool, was predicted by the amount 
and intensity of physical activity, the number of joints affected by pain, and the level 
of depression symptoms reported by participants. Overall HRQoL was reduced by 
decreased participation in physical activities, increasing symptoms relating to 
depression and increased numbers of joints affected by pain.  
 
Current research studies explicitly investigating the mental health manifestations of 
JHS/EDS-HT (115, 120, 122) are limited.  The results of the present research 
therefore provide much needed data specifically relating to the diagnosis of JHS/EDS-
HT, characterising and defining the mental health manifestations of the disorder in 
this specific population.  The mental health of individuals participating in the study 
was investigated using the DASS-21 (Appendix 5), a structured self-report tool 
indicating severity of symptoms relating to the clinical domains of depression, anxiety 
and stress, with questions regarding comorbid diagnoses and the mental health 
domain of the AQoL. The level of symptoms reported by participants in the study 
indicates that a large proportion of the cohort experience at least mild levels of 
symptoms relating to depression, anxiety and stress, with severe to extremely severe 
symptoms related to depression reported in 11%, anxiety in 21% and stress in 19%.  
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Although the DASS-21 is not designed to be used a diagnostic tool for depression, 
anxiety or stress, it is a good indicator of symptom severity in each of these mental 
health domains.   The results of the current study therefore provide much needed 
confirmatory evidence that individuals with a diagnosis of JHS/EDS-HT experience 
symptoms indicative of reduced mental health.   
 
Limitations of the studies: 
The results of the present studies should be viewed within the limitations of their 
design.  The study design was a cross-sectional analysis of individuals with JHS/EDS-
HT, and, as a result, the information gathered represented the symptoms and 
manifestations that individuals were experiencing at one point in time (see Appendix 
1 and 6). Further longitudinal research should be undertaken to provide disease 
progression data in this population.  Structured questionnaires were utilized to 
ascertain the presence and severity of a range of symptoms and to quantify the current 
levels of HRQoL.  Self-report questions were also utilized to identify the presence of 
other comorbid diagnoses or symptoms, which may have resulted in an under-
reporting or bias towards reporting symptoms that participants felt were related to 
their JHS/EDS-HT diagnosis, or inaccurately reporting a previous diagnosis received 
by a medical professional (e.g. JHS or EDS-HT) or providing a “self” diagnosis.  
Attempts were made in the current study to minimize false reporting or reporting of 
“self” diagnoses by specifically asking participants to record diagnoses provided by a 
medical or health professional.  In order to minimize the possibility of such bias in the 
future, structured questionnaires relating to symptoms such as autonomic dysfunction 
and specific questioning on manifestations would be of benefit.  As the study aimed 
purely to investigate the disease presentation in JHS/EDS-HT, there was no control 
group that could provide comparative normative data when determining the 
significance of various findings.  This limitation was overcome to an extent by the use 
of previously published normative and disease data for comparison in determining the 
significance fatigue and HRQoL results.  Nevertheless, where normative data was not 
available for comparison, the results of the study can still be viewed as providing a 
representative description of the experienced manifestations of the disease process in 
the defined population.    
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The results of the Multiple Regression analysis in Study 1 and Study 2 should be 
viewed as being reflective of the study population.  It should be noted that the 
prediction equation identified in each study may differ in an independent sample of 
individuals affected by JHS/EDS-HT. Future research is required to determine if the 
identified predictors in this study population are present in similar adult populations 
affected by JHS/EDS-HT and if improvements in Fatigue and or overall HRQoL are 
possible when addressing the identified predictors.  
 
The study sample was recruited from support groups for connective tissue disorders 
(ConnecTed and EDSAUS) (see Appendix 2), and via word of mouth.  The 
recruitment of individuals from support groups enabled specific recruitment of those 
affected by the condition, and given the absence of any clinics for adults with the 
condition, assisted in locating those who fulfilled the inclusion criteria for the study.  
There was the potential, however, for selection bias with those recruited from support 
groups potentially over-representing those who may be dissatisfied with their medical 
diagnosis and management. Those involved in support groups may be motivated 
toward searching for alternative answers and information to that provided by the 
medical community.  There was a possibility of selection bias when considering 
which participants were able to partake in both the questionnaire and physical 
examination components of the research.  Those who were able to attend the 
University of Sydney at the Lidcombe Campus were able to participate in the physical 
examination.  It is possible those who were more significantly affected by their 
condition and those geographically isolated may not have been able to attend the 
physical examination component of the study.  It should be noted the physical 
examination only provided supplementary data to that obtained via the questionnaires 
in Study One minimizing any potential for bias affecting the results of the study. 
Implications for future research and clinical practice: 
The results of the current studies have several of implications for future research and 
clinical practice in the area of JHS/EDS-HT.  Adequate and timely diagnosis and 
management of individuals with a diagnosis of JHS/EDS-HT was a significant issue, 
and one requiring attention to improve the long-term outcome and disease morbidity 
in this population.  In Sydney, while there is a well-known multidisciplinary clinic for 
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children with JHS/EDS-HT at the large tertiary hospital, The Children’s Hospital at 
Westmead, this service is not available for those over 18 years of age. Many of these 
children are the first generation to receive a diagnosis, their affected parent/s having 
experienced the relatively encapsulated medical areas of rheumatology, dermatology, 
gastroenterology, neurology and ultimately psychiatry without definitive answers.  
 
The proactive use of screening tools to identify and quantify the presence of a range 
of systemic manifestations of the disorder and the development of targeted treatment 
aimed at improving HRQoL and reducing fatigue severity would be likely to result in 
improved outcomes for patients with this disorder.  
 
Improvement in the current diagnostic process: 
While genetic markers have been identified for other EDS subtypes, there is currently 
no identified marker for the hypermobile subtype (136).  The current process used in 
the diagnosis of JHS/EDS-HT remains a confusing, complex and subjective practice, 
with many individuals who seek professional input and diagnosis experiencing 
substantial diagnostic delays, multiple incorrect diagnoses given to explain their 
clinical presentation, and variable education and management for the disorder(62, 
134).  The diagnostic experience described by the current cohort of patients was not 
atypical for the disorder, with the mean delay in diagnosis following first onset of 
symptoms being reported as 20 years (N=53) and with 58% of individuals reporting 
dissatisfaction with the process and subsequent management of their disorder.  Even 
more concerning is the previously reported estimation in 2008 that for every one 
individual diagnosed with JHS/EDS-HT, 19 remain undiagnosed and unmanaged for 
the disorder (134).   The levels of dissatisfaction with diagnosis and management in 
the current cohort is not dissimilar to that reported in other chronic health conditions 
which rely on a diagnosis by exclusion, without definite objective clinical tests or 
procedures being available to confirm the presence of the condition, such as 
fibromyalgia (137) and CFS (138). The dissatisfaction with medical care in CFS was 
significantly associated with long delays in obtaining a diagnosis, inadequate 
explanation regarding the diagnosis and with being incorrectly provided with a 
psychiatric diagnosis for the condition (138).  Similar associations were found in 
fibromyalgia, with those patients dissatisfied with their current medical treatment 
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being more likely to have waited significantly longer for a diagnosis, reported a 
greater number of symptoms related to the disorder, have functional impairment and a 
higher prevalence of chronic widespread pain compared to those who were satisfied 
with their management.  These experiences documented in fibromyalgia and CFS 
mirror those reported by the current cohort of individuals affected by JHS/EDS-HT, 
highlighting the importance of improving the diagnostic process and management 
options provided to patients, with the aim of avoiding lengthy delays and unnecessary 
disease morbidity. The identification of factors contributing to the delay in diagnosis 
and management of individuals with JHS/EDS-HT is essential in order to address this 
issue.  
 
The current diagnostic process for JHS/EDS-HT remains a clinical one based on the 
medical history and physical examination of those affected, following the exclusion 
of other HDCT.  Despite the recognition that JHS and EDS-HT are likely the same 
phenotypic disorder (3, 134), the diagnostic process continues to rely on two separate 
criteria, the Villefranche Criteria for EDS-HT and the Brighton Criteria for JHS, and a 
single diagnostic title is yet to be established referring to the combined diagnosis.  
The diagnosis of JHS/EDS-HT largely relies on the presence of GJH, in addition to 
arthralgia and a range of connective tissue manifestations, however there is 
inconsistency when comparing the Villefranche and Brighton Criteria, with each 
utilising a different Beighton cut-off score to indicate the presence of GJH.   
 
Globally, the accurate identification of GJH is also affected by a lack of international 
consensus on a specific definition for GJH, taking into account age, race, sex and 
even what constitutes normal range of motion in any given joint.  Authors have 
previously recommended the need to develop a universally accepted definition for 
GJH together with standardised testing procedures and cut-off points to establish a 
diagnosis of GJH (10). The standardised Beighton Scoring protocol used in the 
studies that comprise this thesis is included as Appendix 4. 
 
The recognition and variable clinical application of both the Beighton and the 
Brighton in evaluating individuals with symptomatic GJH is likely contributing to the 
variable success experienced by those seeking a diagnosis relating to symptomatic 
GJH.   Explorative studies investigating the knowledge and clinical practice of 
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Rheumatologists (56, 71) and Physiotherapists (71, 139) have identified inconsistent 
use of the Beighton score to establish and diagnosis of GJH, little recognition of the 
systemic nature of the JHS/EDS-HT, and variable use of the Brighton screening tool, 
when attempting to establish a diagnosis for the condition.   The lack of clinical 
knowledge relating to both GJH and JHS/EDS-HT, together with the assessment tools 
currently available, is likely contributing significantly to difficulties experienced by 
individuals affected when attempting to obtain a diagnosis.  Literature reports only 
32% of UK physiotherapists receive formal education relating to JHS (139) while a 
survey of USA physical therapists revealed that 39% were unaware of the existence of 
the condition (71).  There is a clear need for increased education during the training 
phase of health and medical professionals who, in a primary care capacity, are likely 
to encounter undiagnosed individuals with symptoms relating to a connective tissue 
disorder such as JHS/EDS-HT.  Such education will help to ensure there is early 
identification, diagnosis and appropriate referral of those affected by the condition. 
 
While there are objective tests available for several of the signs and symptoms of 
JHS/EDS-HT such as Postural Orthostatic Tachycardia Syndrome, orthostatic 
hypotension, generalised hyperalgesia, gastric transit times, hernias, varicosities and 
prolapses, the lack of specific molecular tests of the condition leaves the diagnostic 
process reliant on clinical reasoning and the exclusion of other HDCTs. This is likely 
to contribute to the delay in diagnosis and implementation of appropriate 
interventions, and the development of subsequent psychosocial manifestations. 
Several authors have recommended further investigation into the molecular basis of 
JHS/EDS-HT, to identify the causal gene/s responsible for the expression of the 
disorder (64, 134, 136).  Due to the heterogeneous nature of JHS/EDS-HT it has been 
hypothesised that instead of one gene accounting for the diagnosis, there may be a 
number of different underlying molecular subtypes accounting for the clinical 
presentation seen in those with a current diagnosis of JHS/EDS-HT (136, 140).  
Regardless of the number of underlying causal genes identified in the future, the 
development of a molecular diagnosis relating to JHS/EDS-HT would be pivotal to 
improving the accuracy and certainty relating to the diagnostic process. 
 
Key recommendations arising from the current thesis are; firstly, the establishment of 
concise objective diagnostic criteria to establish a diagnosis of JHS/EDS-HT, enabled 
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by the development of a single diagnostic label for the disorder, and secondly, that 
future research should aim to establish a molecular diagnosis for the disorder.  
Screening for systemic manifestations and overall quality of life: 
The complex heterogeneous presentation of JHS/EDS-HT poses a significant 
challenge to health and medical practitioners in providing holistic care addressing the 
manifestations of the condition that are not always superficially apparent or 
recognized as impacting on the individuals over all QoL.  The significant contribution 
of systemic manifestations, such as the presence of severe fatigue, gastrointestinal, 
genitourinary, cardiovascular and psychological symptoms, in determining the overall 
morbidity associated with the condition has been documented in previous research, 
highlighting the need for the identification and management of these features (9, 55, 
57). An important finding of the current research was the identification of severe 
fatigue as a highly prevalent manifestation and the most significant systemic feature 
affecting the overall HRQoL in the study population.  This finding echoed the results 
of previous studies identifying fatigue as a manifestation that has the potential to have 
a significant impact on the individual. In addition to fatigue severity, specific 
screening tools were used to establish symptom severity in mental health domains 
(DASS-21) and overall HRQoL in the current study, both of which indicated that the 
defined population experience greater levels of symptoms related to psychological 
distress and worse overall quality of life compared to those not affected by the 
disorder.  The current study supports the conclusion of previous research, which 
identified the importance of evaluating the presence of systemic features of JHS/EDS-
HT needed to improve the assessment and management of patients with this condition 
(55, 133, 141).  
 
Without specific questioning relating to the systemic features associated with 
JHS/EDS-HT, these manifestations may go unreported and unmanaged in many 
individuals.  An example of one such systemic feature is orthostatic dizziness, where 
patients experience dizziness on rising from recumbent positions, after exercise, or 
after a hot shower. If they are sedentary due to pain, fatigue and low levels of physical 
activity, health professionals may attribute the symptom to deconditioning.  The 
connection between the patient’s joint hypermobility, hyperextensible skin, abnormal 
scarring, gastric upset, uterine prolapse and hernia in childhood is not made.  
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Consequently, there is a need to screen and manage systemic features of the condition 
proactively and early in a multidisciplinary manner, potentially reducing the 
morbidity associated with these manifestations.  Features not directly related to the 
connective tissue manifestations are not evaluated during the diagnosis of the 
JHS/EDS-HT, using either the Villefranche or the Brighton criteria. Specific attention 
needs to be placed on incorporating these features, such as fatigue and mental health 
features of the disorder, into the assessment, diagnosis and management of the 
condition.  A fundamental recommendation of the current study is the inclusion of 
specific, short, reliable and valid screening tools following initial diagnosis and 
during the follow-up consultations, to provide valuable information on the systemic 
features of the disorder that require further investigation and management in 
individuals with JHS/EDS-HT.  This recommendation supports previous literature 
advocating the use of appropriate questioning relating to significant systemic features 
in the assessment of multi-system manifestation and HRQoL. Such questioning offers 
the potential to monitor the effectiveness of intervention strategies and modify 
treatments as required (141). 
Management of fatigue and HRQoL in JHS/EDS-HT: 
The holistic management of individuals with JHS/EDS-HT likely lies in the 
development of multidisciplinary interventional programs incorporating strategies to 
address both musculoskeletal and functional impairments experienced by individuals, 
while extending to include strategies to address the myriad of significant non-
musculoskeletal features associated with the disorder. With the identification of a set 
of predictors that can determine the severity of fatigue, the most prevalent of systemic 
features, and overall HRQoL of individuals affected by the condition, there can be a 
new focus on the interventions that are likely to directly improve these important 
aspects of an individual’s lived experience.  Given the wide range of factors that 
potentially influence an individual’s overall fatigue severity and overall HRQoL, the 
results of study one allow the development of a targeted multidisciplinary approach to 
the management of individuals with JHS/EDS-HT.  
 
There have been strong recommendations for the development of multidisciplinary 
approach to the management of the individuals affected by JHS/EDS-HT (9, 57, 64).  
With limited studies investigating the management of JHS/EDS-HT and the specific 
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use of multidisciplinary teams, the identification of aspects of the condition that 
contribute to fatigue severity and the overall HRQoL experienced by individuals 
affected by the disorder opens the door for substantial improvements in the current 
evidence-based management strategies in this population.  Current management 
strategies utilising a multidisciplinary team approach have predominately focused on 
functional and pain related measures to determine the effectiveness of strategies (129, 
130, 132).  HRQoL measures have been utilized by a number of studies in the 
evaluation of the overall effect of the management strategies (129), however fatigue 
severity has not featured as a specific outcome measure in previous research.   
 
Based on the results of the current research, the inclusion of management strategies to 
address levels of physical activity participation, coping strategies to improve 
participation in community and family interactions, pain management, psychological 
intervention, investigation and management of orthostatic intolerance and education 
regarding the disorder and potential management strategies, may help to reduce both 
fatigue severity and improve overall HRQoL. To evaluate the efficacy of intervention 
strategies targeting overall HRQoL and fatigue severity, measures specifically 
assessing both these features should be utilized as outcome measures in future 
research. 
 
One important consideration in the development of management strategies for 
JHS/EDS-HT is the high reported levels of patient dissatisfaction with their medical 
management.  Previous research has identified that when a patient is actively involved 
in the management and decision making process and is allowed to ask questions 
related to their diagnosis, there are greater levels of psychological well-being (142), 
increased satisfaction with their healthcare provider, and a greater sense of control 
over their illness (143).  Given the multi-system nature of JHS/EDS-HT and the 
potential number of management strategies that could be implemented to address all 
manifestations of the disorder, careful consideration should be paid to the likely 
compliance and ability of an individual to address all features of the condition.  The 
management of an individual with JHS/EDS-HT would be best managed with a single 
physician who is responsible for coordinating multi-disiplinary care for the individual 
affect by JHS/EDS-HT.  Attention should be paid to the importance of patient 
education and “choice” in determining which treatment options are implemented in 
 98 
the management of their condition.  There is likely efficacy in addressing individual 
contributors to fatigue severity and overall HRQoL, rather than taking an all or 
nothing approach to the condition, and possibly a realistic management approach in 
JHS/EDS-HT.  Such an approach has proven effective in the secondary reduction of 
cardiac risk following a cardiac event compared to conventional care, with patients 
who made an educated choice as to which cardiac risk factor they wished to 
specifically address showing greater improvements not only in the individual risk 
factors but also across the global coronary risk profile (144).  Such a finding indicates 
that patient centered-care with guided self-determination of treatment choices may be 
a beneficial management strategy in conditions such as JHS/EDS-HT, where the 
disorder is associated with numerous disease manifestations and potential 
management options.   Further specific research into the efficacy of such an 
intervention in JHS/EDS-HT is necessary to determine if this approach could not only 
improve specific patient outcomes related to disease manifestations and HRQoL, but 
also improve patient satisfaction with their disease management.    
 
Conclusion: 
This thesis provides a detailed description of the type and range of manifestations 
associated with a diagnosis of JHS/EDS-HT.  The identification of fatigue severity as 
a significant non-musculoskeletal manifestation of the disorder, and the subsequent 
determination of the potential predictors of both fatigue severity and the overall 
HRQoL, provide new information that is likely to progress the management of the 
disorder.  The findings confirm that JHS/EDS-HT is not only a multisystem condition 
but a complex systemic disorder that has the potential to result in significant disease 
morbidity, functional impairment and disability.  The results of this thesis provide 
promising direction for future research, to assess the efficacy of management 
strategies addressing the identified predictors of fatigue severity and HRQoL, with the 
aim of improving the life experience of those affected by JHS/EDS-HT.      
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What is the study about? 
Many children, adolescents and adults are hypermobile (have loose or double joints). We think they have 
more musculoskeletal pain and fatigue and are at higher risk of sports injury than people who are not 
hypermobile. Because joint hypermobility is sometimes accompanied by widely varying symptoms and signs 
- including joint pains, joint instability, brittle bones, lax joints, fragile stretchy skin, tendency to bruise, 
hernias and prolapse and poor balance, some of these people will have seen medical and allied health 
professionals and have been undiagnosed. We aim to look at the prevalence of the broad range of signs and 
symptoms in an adult population of individuals who perceive themselves to be hypermobile. 
    
     (2 Who is carrying out the study? 
    
(3
 
What does the study involve? 
We will ask you to complete a questionnaire that will include information related to your age, gender, 
ethnicity and activity level. You will also be asked about joint and soft tissue soreness, joint instability 
episodes, family history of joint hypermobility, fatigue, fainting episodes, stress incontinence, gastrointestinal 
symptoms and history of low trauma fractures. 
  A normative study of Generalised Joint Hypermobility Syndrome. 
Version 2, 16 07 12 
Page1 of 2 
A/Prof Leslie Nicholson 
 
Associate Professor, Discipline of 
Biomedical Sciences, Sydney medical 
School, The University of Sydney 
Ph: 02 9351 9369 
 
Dr Louise Tofts 
 
Staff Specialist, 
Paediatric Rehabilitation 
Medicine 
Ph. 02 9845 2132 
 
Miss Verity Pacey 
 
Senior Physiotherapist and PhD 
candidate 
Childrens' Hospital Westmead 
Ph. 02 9845 3369 
 
Dr Bronwen Ackermann 
 
Senior Lecturer, 
Discipline of Biomedical 
Sciences, Sydney 
Medical School, The 
University of Sydney 
Ph. 02 9519 4084 
 
Ms Anne Krahe 
 
Orange Health Services Orange Ph. 04xx xxx xxx 
 
 
Appendix 1: Participant information statement JHS/EDS-HT and GJH Study 
 
 111 
We will record your height and weight; screen for joint hypermobility using the Beighton score (tests the joint 
range in your thumbs, little fingers, elbows, knees and spine). Then we will check your skin for elasticity and 
assess the thickness of your skin using diagnostic ultrasound, test for hypermobility in your hips, knees and 
ankles, assess your foot posture in standing and test your shoulder, wrist and knee joint laxity. We will ask 
you to perform a balance test on single leg stance on both legs. 
If you are currently experiencing any joint or muscle pain, please inform the assessor as we will omit the 
tests relevant to these areas. If you have widespread joint/muscle pain we may exclude you from 
participation and suggest you seek a medical opinion. Please let the assessor know if you have 
experienced any episodes of knee-cap or shoulder dislocation. 
All testing will be performed at the Faculty of Health Sciences (Lidcombe), Narrabeen Sports Medicine Centre 
or at your home at a time that suits you. No testing will cause you any pain. You will be informed of your 
personal results at the time of testing. 
(4
 
How much time will the study take? 
Completing the questionnaires and testing should take 45 minutes to 1 hour of your time, on one occasion 
only. 
(5
 
Can I withdraw from the study? 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do 
consent - you can withdraw at any time without affecting your relationship with The University of Sydney, or 
the Narrabeen Sports Medicine Centre.. 
(6
 
Will anyone else know the results? 
All aspects of the study, including results, will be strictly confidential and only the researchers will have 
access to information on participants 
A report of the study may be submitted for publication, but individual participants will not be identifiable in 
such a report. 
(7
 
Will the study benefit me? 
We cannot and do not guarantee or promise that you will receive any benefits from the study. If we identify 
problems you have which would get better with treatment we will refer you for appropriate treatment. We 
hope the results from the study will allow us to understand your condition better and be able to provide the 
medical and allied health professions with better diagnostic information. This information will also allow us to 
plan future studies of treatments for this condition. 
(8
 
Can I tell other people about the study? 
You are welcome to direct others to our posters if they are interested in participating in this study. 
(9
 
What if I require further information about the study or my involvement in it? 
When you have read this information, Dr Nicholson will discuss it with you further and answer any questions 
you may have. If you would like to know more at any stage, please feel free to contact any   of the 
researchers (see point 2 on the previous page) 
(10
 
What if I have a complaint or any concerns? 
Any person with concerns or complaints about the conduct of a research study can contact The Manager, 
Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
This information sheet is for you to keep 
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Appendix 2: Online introduction for JHS/EDS-HT Study: 
At the University of Sydney we are undertaking 2 streams of research into 
heritable disorders of connective tissue. One stream is paediatric in 
collaboration with the Children’s Hospital at Westmead and the other is an 
adult stream. As physiotherapists and rehab physicians we are particularly 
interested in the effects of joint hypermobility on health and wellbeing. 
We are currently recruiting people between the ages of 16 and 75 who have 
joint hypermobility for a study to look at the systemic and musculoskeletal 
signs and symptoms and how these affect quality of life. If you have been 
diagnosed with Joint Hypermobility Syndrome or Ehlers-Danlos Syndrome 
(Type III or hypermobility type) you may qualify for the study. 
The study is being conducted at the Faculty of Health Science in Lidcombe 
(Sydney). Participation would involve completing some questionnaires (we 
can send them to you electronically so you can complete them at your leisure) 
and an assessment of your joint and soft tissue hypermobility (should take 
about 1 hour). 
Understanding hypermobility and getting the research “out-there” to medical 
and allied health professionals is an important step in improving the lives of 
people with these diseases. 
Even if you cant get to Sydney but would like to participate, you can complete 
the questionnaire portion of the study. If you would like more information 
regarding this study or you would like to participate, please contact: 
Anne Krahe – akra2983@uni.sydney.edu.au OR ph. 04xx xxx xxx 
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Appendix 4 AQoL-6D 
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Appendix 5 DASS-21 
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Appendix 6 Standardised Beighton Scoring Protocol 
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Appendix 7: Variable collected in questionnaire and physical 
examination for Study 1 and 2 (* = Study 1 only) 
 
Variables collected in questionnaire and physical examination (*) for Study 
1 and 2  
Sex 
Age 
JHS/ EDS – HT Diagnosis  
Family history hypermobility 
Diagnosis of EDS/OI/ Marfan/other connective tissue disorder 
Hakim 5 
Number of joints affected by pain attributed to GJH on body chart 
Soft tissue pain noted on body chart 
History of joint dislocation - listed joints  
Fracture history 
Sporting history 
Ease of bruising measured on VAS 
Incontinence measured on VAS 
Dizziness measured on VAS 
Stool Frequency  
History of hernia  
Fatigue Severity Score (FSS) 
Satisfaction with diagnosis and management related to diagnosis relating to GJH 
Previous surgery for Connective tissue features of the disorder 
Physical activity index 
Sleep related questions 
Previous medical diagnosis  
DASS- 21 questionnaire 
AQOL_6D questionnaire 
Beighton Score * 
Weight KG * 
Height m * 
BMI * 
Marfanoid Habitus * 
Skin Signs * 
Eye signs * 
Duration Symptoms prior to diagnosis  
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Appendix 8: STROBE Checklist for study 2 
STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No. Recommendation 
Relevant section and Page  
No. in manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract See abstract and study title page  
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found 
See abstract page  
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Refer to introduction  
Objectives 3 State specific objectives, including any prespecified hypotheses Refer to the last paragraph of the introduction 
Methods 
Study design 4 Present key elements of study design early in the paper Refer to first paragraph of introduction  
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, 
follow-up, and data collection 
Refer to first paragraph of introduction  
Participants 6 (a) Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection 
of participants 
Refer to first paragraph of the introduction 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. 
Give diagnostic criteria, if applicable 
Refer to the metholdology section of the paper 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group 
Refer to the methodology section of the paper and 
relevant references  
Bias 9 Describe any efforts to address potential sources of bias Refer to limitation section of the conclusion of the 
thesis.  
Study size 10 Explain how the study size was arrived at Refer to Figure 1.1 
Continued on next page 
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Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why 
Refer to the methodology   
Statistical 
methods 
12 (a) Describe all statistical methods, including those used to control for confounding See statistical analysis section of methodology  
(b) Describe any methods used to examine subgroups and interactions N/A  
(c) Explain how missing data were addressed N/A  
(d) Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy 
N/A  
(e) Describe any sensitivity analyses N/A  
 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
See Figure 1.1 in results section.  
(b) Give reasons for non-participation at each stage As above  
(c) Consider use of a flow diagram As above   
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders 
See results section first paragraph  
(b) Indicate number of participants with missing data for each variable of interest See results section   
Outcome data 15* Cross-sectional study—Report numbers of outcome events or summary measures See results section and relevant tables. 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision 
(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were 
included 
N/A  
(b) Report category boundaries when continuous variables were categorized See methodology and results   
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
N/A  
Continued on next page 
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Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses See methodology and result section of paper  
Discussion 
Key results 18 Summarise key results with reference to study objectives See first paragraph of the discussion  
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
See limitation section of conclusion chapter of 
thesis 
 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
See discussion section of paper   
Generalisability 21 Discuss the generalisability (external validity) of the study results See discussion section of the paper   
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based 
See disclosure statement   
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The 
STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal 
Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/).  
 
